Chaan S. Ng
    Title Professor of Diagnostic Radiology, MD Anderson Cancer Center; Visiting Professor, Sun Yat-sen University Cancer Center (2016.7-2019.7)

    Prof. Ng received his PhD in Radiology Medicine in the Christ's College, University of Cambridge in 2015 and now he is working as a professor in the Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX. He has the expertise, leadership, training, expertise and motivation necessary to successfully carry out the proposed research project. He is a radiologist specializing in Body Imaging (Abdomen and Pelvis), with extensive experience in CT, MRI and PET. He is actively involved in the development and evaluation of imaging techniques, including dynamic contrast enhanced, or perfusion, computed tomography (DCE-CT). He has been involved in multiple clinical trials utilizing these techniques in the context of targeted therapeutic agents. He has had specific and extremely fruitful collaborations with the Phase 1 Clinic Trials, Gastrointestinal (Dr James Yao) and Genitourinary teams over the last 15 years. He successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project.

    Research Interest(s)
    1. Computed tomography (CT) detecting colorectal cancer in elderly patients
    2. Assessing efficacy of radiological and dother diagnostic tests
    3. CT and MRI perfusion
    4. CT perfusion

    1. Computed tomography (CT) detecting colorectal cancer in elderly patients:

    a. Ng CS, Doyle TC, Pinto EM, Courtney HM, Miller R, Bull RK, Freeman AH, Dixon AK. Caecal carcinomas in the elderly: useful signs in minimal preparation CT. Clin Radiol. 2002 May;57(5):359-64. PubMed PMID: 12014932.

    b. Ng CS, Doyle TC, Pinto EM, Courtney HM, Bull RK, Prevost AT, Campbell GA, Freeman AH, Dixon AK. Evaluation of CT in identifying colorectal carcinoma in the frail and disabled patient. Eur Radiol. 2002 Dec;12(12):2988-97. PubMed PMID: 12439581.

    c. Ng CS, Doyle TC, Courtney HM, Campbell GA, Freeman AH, Dixon AK. Extracolonic findings in patients undergoing abdomino-pelvic CT for suspected colorectal carcinoma in the frail and disabled patient. Clin Radiol. 2004 May;59(5):421-30. PubMed PMID: 15081847.

    d. Ng CS, Wei W, Doyle TC, Courtney HM, Dixon AK, Freeman AH. Minimal-preparation abdomino-pelvic CT in frail and elderly patients: prognostic value of colonic and extracolonic findings. Clin Radiol. 2008 Apr;63(4):424-32. PubMed PMID: 18325363.

    2. Assessing efficacy of radiological and dother diagnostic tests:

    a. Ng CS, Watson CJ, Palmer CR, See TC, Beharry NA, Housden BA, Bradley JA, Dixon AK. Evaluation of early abdominopelvic computed tomography in patients with acute abdominal pain of unknown cause: prospective randomised study. BMJ. 2002 Dec 14;325(7377):1387. PubMed PMID: 12480851; PubMed Central PMCID: PMC138513.

    b. Ng CS, Palmer CR. Analysis of diagnostic confidence and diagnostic accuracy: a unified framework. Br J Radiol. 2007 Mar;80(951):152-60. PubMed PMID: 17329682.

    c. Ng CS, Palmer CR. Assessing diagnostic confidence: a comparative review of analytical methods. Acad Radiol. 2008 May;15(5):584-92. PubMed PMID: 18423315.

    d. Ng CS, Palmer CR. Analysis of diagnostic confidence: application to data from a prospective randomized controlled trial of CT for acute abdominal pain. Acta Radiol. 2010 May;51(4):368-74. PubMed PMID: 20350244.

    3. CT and MRI perfusion:

    a. Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug;189(2):378-85. PubMed PMID: 17646464.

    b. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010 Jan;194(1):166-71. PubMed PMID: 20028919.

    c. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol. 2010 Feb;194(2):W134-40. PubMed PMID: 20093564.

    d. Ng CS, Charnsangavej C, Wei W, Yao JC. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011 Mar;196(3):569-76. PubMed PMID: 21343498.

    4. CT perfusion:

    a. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol. 2010 Feb;194(2):W134-40. PubMed PMID: 20093564.

    b. Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R, Charnsangavej C. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology. 2011 Sep;260(3):762-70. PubMed PMID: 21788525; PubMed Central PMCID: PMC3156998.

    c. Ng CS, Hobbs BP, Chandler AG, Anderson EF, Herron DH, Charnsangavej C, Yao J. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. Radiology. 2013 Dec;269(3):758-67. PubMed PMID: 23824990; PubMed Central PMCID: PMC4228711.

    d. Ng CS, Hobbs BP, Wei W, Anderson EF, Herron DH, Yao JC, Chandler AG. Effect on perfusion values of sampling interval of computed tomographic perfusion acquisitions in neuroendocrine liver metastases and normal liver. J Comput Assist Tomogr. 2015 May-Jun;39(3):373-82. PubMed PMID: 25626401; PubMed Central PMCID: PMC4433407.

    Yibin Kang
    Title Professor of Molecular Biology, Princeton University

    Dr. Yibin Kang is a Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University. He graduated with a bachelor's degree from Fudan University in Shanghai in 1995. After completing his graduate study at Duke in 2000, Dr. Kang became an Irvington Institute postdoctoral fellow with Dr. Joan Massagué at the Memorial Sloan-Kettering Cancer Center and pioneered a functional genomic approach to elucidate mechanism of breast cancer metastasis. Dr. Kang joined the faculty of Princeton University as an Assistant Professor of Molecular Biology in 2004. He was promoted to Associate Professor with tenure in 2010 and to Endowed Chair Full Professor in 2012.

    Dr. Kang's research focuses on the molecular mechanisms of breast cancer metastasis. His laboratory applies a multidisciplinary approach to analyze the molecular basis of cancer metastasis, combining molecular biology and genomics tools with animal models and advanced in vivo imaging technologies. Dr. Kang has published over 100 original articles in leading journals including Cell, Cancer Cell, and Nature Medicine. His work discovered new genes that promote recurrence, metastasis and chemoresistance of breast cancer, delineated tumor-stromal interactions that are essential for metastatic growth, and identified novel regulators with dual functions in mammary gland cell fate determination and tumor progression. Dr. Kang's outstanding achievements have been recognized by many prestigious awards, including a Department of Defense Era of Hope Scholar Award and the 2011 Vicek Prize for Creative Promise in Biomedical Sciences, a prestigious award honoring foreign-born artists and scientists who have demonstrated exceptional creativity and originality in the early stages of their careers in the United States. Dr. Kang is also the recipient of the 2012 AACR Award for Outstanding Achievements in Cancer Research, the Fuller Albright Award of the American Society of Bone and Mineral Research, and the 2014 Josh Fidler Innovation in Metastasis Research Award from the Metastasis Research Society. Dr. Kang was a member of the Board of Directors of the Metastasis Research Society from 2008 to 2012. He was elected as the President of the society in 2014 and will serve his term from 2016 to 2018.

    Research Interest(s)

    Molecular Mechanisms of Cancer Metastasis
    The difference between life and death for most cancer patients hinges on the degree of spread, or metastasis, of their tumors. Therefore, a better molecular understanding of cancer metastasis holds significant promise for reducing mortality and morbidity from cancer. The central theme of our research is a multidisciplinary and integrative approach to the analysis of the molecular basis of cancer metastasis, combining molecular biology and genomics tools with animal models and advanced in vivo imaging technologies. We focus on the identification of metastasis genes and functional characterization of their involvement in tumor-stromal interactions during the formation of metastasis in different organs. We are also interested in regulators of mammary gland development and early oncogenic events that may have significant impact on tumor progression and metastasis.

    Identification of novel metastasis genes through integrative genomics
    Discovering metastasis genes that are clinically relevant and functionally important are critical for the development of novel therapeutics. We use two complementary approaches to harness the power of comprehensive profiling technologies, including genomics, proteomics and metabolomics, for the identification and validation of novel metastasis genes and pathways. Using a large collection of mouse models of cancer metastasis available in our laboratory, we identify candidate metastasis genes by genomic profiling of highly metastatic cells derived after in vivo selection. Functional characterization of these genes revealed the novel activities of several developmentally conserved pathways, including the EGFR, TGFb, and Notch pathways, in mediating tumor-stromal interactions essential for the formation of metastasis in vital organs such as bone, lung and brain. Importantly, pharmaceutical inhibitors against these signaling pathways are highly effective in reducing the development of metastasis, suggesting novel avenues for clinical management of metastatic cancer. We also developed integrative genomics strategies to utilize available clinical genomic profiling and sequencing data of human cancer to identify genetic alterations with functional impact on cancer metastasis. Using this approach, we identified Metadherin (MTDH) as a dual-functional gene that promotes metastasis and broad-spectrum chemoresistance of breast cancers. Ongoing studies in the lab are currently characterizing MTDH and additional candidate metastasis genes.

    Molecular characterization of tumor stromal interactions in metastasis
    It has become well-recognized that metastatic cancer cells do not act autonomously when they escape from the primary tumor and establish colonies at different organs. Rather, intricate interactions between tumor cells and their stromal microenvironment play an essential role in the pathogenesis of metastasis. Our laboratory uses a series of in vitro and in vivo models systems to dissect the molecular cross-talks between tumor cells and resident stromal cells. Advanced in vivo imaging technologies are being developed in the lab to analyze the signaling pathway dynamics and cellular interactions that occur at real time during the development and treatment of metastatic diseases. Such studies are crucial for the development of highly effective therapeutics against metastatic cancer.

    The role of mammary gland stem cells in development and breast cancer
    Although it was initially believed that metastasis capacity is acquired late during tumor progression, substantial evidence suggests that different early transformation events may set the resulting tumors on distinct paths towards either aggressive metastasis or slow progression. In recent years, the intriguing link between mammary stem cells (MaSCs) and breast cancer stem cells has generated tremendous interest due to its important implications in breast cancer etiology and therapeutics. Identifying the cellular origin of breast cancer will not only aid in understanding the early events that drive breast carcinogenesis, but will also yield critical insights to help understand the different tendencies of metastasis in different subtypes of breast cancer. In order to facilitate the study of MaSCs during tumorigenesis and metastasis, we recently developed a mouse model in which MaSCs can be detected by MaSC-specific expression of luciferase in the mammary epithelium. Using this model system, we will now investigating the regulation of MaSCs by canonical stem cell signaling pathways and breast cancer oncogenes, test the susceptibility of MaSCs, progenitor cells and differentiated cells to transformation, and study how the tumorigenic and/or metastatic potential of the resulting tumors are influenced by their cellular origin.

    miRNAs and ncRNAs as regulators of tumor progression
    miRNAs and other non-coding RNAs (ncRNAs) have emerge in recent years as important regulators of critical physiological and pathological processes. We recently discovered the miR-200 family of miRNAs as important regulators of epithelial-mesenchymal transition, which is believed to be the initial step of metastasis that enables the migration and invasion of tumor cells. We are using xenograft and transgenic mouse models to investigate the function of EMT-related miRNAs. Similar research strategy is being applied to identify and characterize other miRNAs and ncRNAs that may play a crucial role in different stage of tumor progression.

    1. Alexia C, Carvalho G, Poalas K, Zemirli N, Carvalho G, Zemirli N, Dwyer J, Dubois S, Hatchi E, Cordeiro N, Smith SS, Castanier C, Le Guelte A, Wan L, Kang Y, Vazquez A, Gavard J, Arnoult D, and Bidère N (2013) The endoplasmic reticulum acts as a platform for ubiquitylated components of nuclear factor κB signaling. Science Signaling, 6(291):ra79.

    2. Smith HA and Kang Y (2013) Acute infection induces a metastatic niche: a double menace for cancer patients. Clin. Cancer Res.. 19(17):4547-9.

    3. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, and Kang Y. (2013) Tumor-induced miRNA changes in osteoclast as mediators and biomarkers of osteolytic bone metastasis. Cancer Cell.  24:542-56.

    4. Esposito M and Kang Y. (2013) Molecular therapeutics for bone metastasis. Pharmacology & Therapeutics, S0163-7258(13)00211-8.

    5. Wan L, Pantel K, and Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nature Medicine, 19:1450-1464.

    6. Ell B and Kang Y. (2013) MicroRNAs as regulators of tumor-associated stromal cells. Oncotarget, 4:2165-6.

    7. Deng Y, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, Zhang X, Shen M, Yan X, Wang L, Wang X, Kang Y, Si J, and Zhou T (2014) MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett.  342:27-35.

    8. Fan J, Shan C, Kang H-B, Elf S, Xie J, Tucker M, Gu T-L, Aguiar M, Lonning S, Chen H, Mohammadi M, Britton LP, Garcia BA, Aleckovic M, Kang Y, Kaluz S, Devi N, Van Meir E, Hitosugi T,1, Seo JH, Lonial S, Gaddh M, Arellano M, Khoury HJ, Khuri FR, Boggon TJ, Kang S, Chen J. (2014) Tyr-phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate pyruvate dehydrogenase complex. Mol. Cell, 53(4):534-48.

    9. Wang Y, Lei R, Zhuang X, Zhang N, Pan H, Li G, Hu J, Pan X, Tao Q, Fu D, Xiao J, Kang Y, Yang Q, and Hu G. (2014) DLC1-dependent parathyroid hormone-like inhibition suppresses breast cancer bone metastasis. J. Clin. Invest., 124(4):1646-59.

    10. Li W and Kang Y (2014) A new lnc in metastasis: long non-coding RNA mediates the pro-metastatic function of TGF-β. Cancer Cell, 25(5):557-9.

    11. Wan L, Lu X, Yuan S, Wei Y, Guo F, Shen M, Yuan M, Chakrabarti R, Hua YSmith HA, Blanco MA, Chekmareva M, Wu H, Zheng A, Bronson RT, Haffty BG, Xing Y, and Kang Y (2014) MTDH-SND1 interaction is essential for the expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer Cell, 26(1):92-105.

    12. Ell B and Kang Y. (2014) MicroRNAs as regulators of bone homeostasis and bone metastasis. BoneKEy Reports, 3:549.

    13. Cicchini M, Chakarabarti R, Kongara S, Price S, Nahar R, Lozy F, Hua Zhong H, Vasquez A, Kang Y and Karantza V. (2014) Monoallelic Becn1 loss deregulates the mammary cell hierarchy and promotes parity-associated and WNT1-driven mammary tumorigenesis.  Autophagy, 10(11): 2036-52.

    14. Zheng H, Shen M, Cha Y-L, Li W, Wei Y, Blanco MA, Ren G, Zhou T, Storz P, Wang H-Y, and Kang Y. (2014) PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell, 26:358-373.

    15. Ell B, Qiu Q, and Kang Y (2014) The miRNA-23b/27b/24 cluster promotes breast cancer lung metastasis through inhibition of PSAP. J. Biol. Chem., 289(32):21888-95.

    16. Wan L, Hu G, Wei Y, Yuan M, Bronson RT, Yang Q, Siddiqui J, Pienta KJ and Kang Y. (2014) Genetic ablation of metadherin inhibits spontaneous prostate cancer progression and metastasis in mice. Cancer Research, 74(18):5336-47.

    17. Guo F*, Wan L*, Zheng A, Stanevich V, Chen H, Wei Y, Satyshur KA, Shen M, Lee W, Kang Y# and Xing Y#. (2014) The structure of MTDH-SND1 complex reveals novel cancer-promoting interactions. Cell Report, 8(6):1704-13. #Co-corresponding authors.

    18. Chakrabarti R, Wei Y, Hwang J, Hang X, Blanco MA, Choudhury A, Tiede B, Romano R-A, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, and Kang Y. (2014)  Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signaling. Nature Cell Bio, 16(10):1004-15.

    19. Alečković M and Kang Y. (2014) Regulation of cancer metastasis by cell-free miRNAs. Biochim. Biophys. Acta Reviews on Cancer, 1855(1):24-42.

    20. Mathias RA, Greco TM, Oberstein A, Budayeva HG, Chakrabarti R, Kang Y, Shenk S, and Cristea IM. (2014) Sirtuin 4 is a lipoamidase regulating the activity of the pyruvate dehydrogenase complex. Cell, 159(7) 1615–1625.

    21. Wong KL, Li W, An Y, Duan Y, Kang Y, and Yan Y.  (2015) β-Spectrin regulates the Hippo signaling pathway and modulates the basal actin network. J Biol. Chem., 290(10):6397-407.

    22. Chakrabarti and Kang Y. (2015) Transplantable mouse tumor models of breast cancer metastasis. Methods Mol. Biol., 1267:367-80.

    23. Zheng H, and Kang Y. (2015) Cradle of evil: osteogenic niche for early bone metastasis. Cancer Cell, 27:153-155.

    24. Esposito M, and Kang Y. (2015) RAI2: linking retinoic acid signaling with metastasis suppression. Cancer Discovery, 5(5) 458-460.

    25. Ren G, Esposito M, and Kang Y. (2015) Bone metastasis and the metastatic niche. J Mol Med. 93(11):1203-12.

    26. Alečković M and Kang Y. (2015) Bone marrow stroma-derived miRNAs as regulators, biomarkers and therapeutic targets of bone metastasis. Bonekey Rep. 4:671-8.

    27. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Kosaka S, Di Giannatale A, Ceder S, Singh S, Williams  C, Ararso Y, Kure EH, Mallya K, Batra SK, Vinagolu RK, Fodstad O, Muller V, Pantel K, Bissell MJ, Ghajar C, Garcia BA, Kang Y, Matei I, Peinado H, Bromberg J, and Lyden D. (2015) Tumor exosome integrins determine organotropic metastasis. Nature, 527(7578):329-35.

    28. Alečković M and Kang Y. (2015) Welcoming treat: astrocyte-derived exosomes induce PTEN suppression to foster brain metastasis. Cancer Cell, 28: 554-6.

    29. Kang Y. (2016) Imaging TGFβ signaling in mouse models of cancer metastasis. Methods Mol. Biol., 1344:219-32.

    30. Li W and Kang Y. (2016) Probing the fifty shades of EMT in metastasis. Trends in Cancer, in press.

    31. Alesi GN, Jin L, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Chen J, Khuri FR, and Kang S. (2016) RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. Oncogene, in press.

    32. Bednarz-Knoll N, Efstathiou A, Gotzhein F, Wikman H, Mueller V, Kang Y, and Klaus Pantel. (2016) Potential involvement of Jagged1 in metastatic progression of human breast carcinomas. Clin. Chem., in press.

    33. Zhao P, Wei Y, Qiu Q, Xu Y, Kang Y and Cheng C. (2016) The CD44s splice isoform is a central mediator for invadopodia activity. J. Cell Science, in press.

    34. Celià-Terrassa T and Kang Y. (2016) Distinctive properties of metastasis initiating cells. Genes & Development, in press.

    35. Hu J-Y, Yi W, Deng R, Zhang M-Y, Xu R, Zeng L-S, Long X-R, Zhou X-M, Zheng XF, Kang Y*, Wang H-Y*. (2016) MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. Oncology Letters, in press. (*co-corresponding authors)


    Baowei Fei
    Title Associate Professor, Emory University, Visiting Professor, Sun Yat-sen University Cancer Center (2016.1-2019.1)

    Dr. Fei is Director of the Quantitative BioImaging Laboratory (QBIL). He is a faculty member in the Department of Radiology and Imaging Sciences and the Department of Mathematics and Computer Sciences at Emory University. He is also a faculty member in the Joint Department of Biomedical Engineering at Emory University School of Medicine and Georgia Institute of Technology. Dr. Fei joined the Division of Physics and Computing in the Department of Radiology at Emory University after leaving Case Western Reserve University in Cleveland, Ohio, where he was in charge of the Multimodality Image Analysis Laboratory. Through his extensive research involvement, Dr. Fei has presented internationally and is widely published. He serves as an Associate Editor for Medical Physics, an Editorial Board Member for Clinical Medicine - Urology, a Program Committee Member for SPIE Medical Imaging, and a reviewer for more than 10 international journals in medical imaging. Dr. Fei's research on prostate cancer imaging and image-guided therapy was highlighted by the Department of Defense in 2006. Dr. Fei's NIH-supported research has emphasized applying multimodality molecular imaging (PET/MRI) to study early tumor response to therapy. In 2009, Dr. Fei was selected as a Georgia Cancer Coalition Distinguished Scholar. In his laboratory, Dr. Fei enjoys mentoring undergraduate and graduate students, post-doctoral fellows, and residents when they undertake research projects.

    Research Interest(s)
    Dr. Fei's current research projects include advanced computer algorithms for medical processing and analysis, image-guided minimally invasive therapy, and multimodality molecular imaging.

    1. Fei BW, Nieh PT, Schuster DM, Master VA. PET directed, 3D ultrasound-guided prostate biopsy, Diagnostic Imaging Europe, Pages: 12-15, Jan. 2013 (Featured by the journal cover)

    2. *Wang H, Fei BW (corresponding author). Nonrigid point registration for 2D curves and 3D surfaces and its various applications. Phys Med Biol. 2013 Jun 21;58(12):4315-30.

    3. *Yang X, Fei BW (corresponding author). Multiscale segmentation of the skull in MR images for MRI-based attenuation correction of combined MR/PET. J Am Med Inform Assoc. 2013 Jun 12. [Epub ahead of print] PubMed PMID: 23761683.

    4. Zhen Z, Tang W, Guo C, Chen H, Lin X, Liu G, Fei BW, Chen X, Xu B, Xie J. FerritinNanocages To Encapsulate and Deliver Photosensitizers for Efficient Photodynamic Therapy against Cancer. ACS Nano. 2013 Jul 11. [Epub ahead of print] PubMed PMID: 23829542.

    5. *Qin X, Cong Z, Fei BW (corresponding author). Automatic segmentation of right ventricular ultrasound images using sparse matrix transform and a level set. Phys Med Biol. 2013 Nov 7;58(21):7609-24. doi: 10.1088/0031-9155/58/21/7609. Epub 2013 Oct 10. PubMed PMID:24107618; PubMed Central PMCID: PMC3925785. (*Postdoctoral fellow)

    6. Sechopoulos I, Bliznakova K, Fei BW. Power spectrum analysis of the x-ray scatter signal in mammography and breast tomosynthesis projections. Med Phys. 2013 Oct;40(10):101905. doi: 10.1118/1.4820442. PubMed PMID: 24089907; PubMed Central PMCID: PMC3785536

    7. *Lu G, Fei BW (corresponding author). Medical hyperspectral imaging: a review. J Biomed Opt. 2014 Jan;19(1):10901. doi: 10.1117/1.JBO.19.1.010901. PubMed PMID: 24441941; PubMed Central PMCID: PMC3895860 (* PhD student).

    8. Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei BW, Alexander RW. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014 Dec 19;3(6). pii: e001202. doi: 10.1161/JAHA.114.001202. PubMed PMID: 25527624.

    9. Lu G, Halig L, Wang D, Qin X, Chen ZG, Fei BW. Spectral-spatial classification for noninvasive cancer detection using hyperspectral imaging. J Biomed Opt. 2014 Oct;19(10):106004. doi: 10.1117/1.JBO.19.10.106004. PubMed PMID: 25277147; PubMed Central PMCID: PMC4183763.

    10. Liu H, Wang J, Xu X, Song E, Wang Q, Jin R, Hung CC, Fei BW. A robust and accurate centerfrequency estimation (RACE) algorithm for improving motion estimation performance of SinMod on tagged cardiac MR images without known tagging parameters. Magn Reson Imaging. 2014 Nov;32(9):1139-55. doi: 10.1016/j.mri.2014.07.005. Epub 2014 Aug 1. PubMed PMID: 25087857.

    11. Qin X, Fei BW. Measuring myofiber orientations from high-frequency ultrasound images using multiscale decompositions. Phys Med Biol. 2014 Jul 21;59(14):3907-24. doi: 10.1088/0031- 9155/59/14/3907. Epub 2014 Jun 24. PubMed PMID: 24957945; PubMed Central PMCID: PMC4137038.

    12. Malliori A, Bliznakova K, Sechopoulos I, Kamarianakis Z, Fei BW, Pallikarakis N. Breast tomosynthesis with monochromatic beams: a feasibility study using Monte Carlo simulations. Phys Med Biol. 2014 Aug 21;59(16):4681-96. doi: 10.1088/0031-9155/59/16/4681. Epub 2014 Aug 1.PubMed PMID: 25082791; PubMed Central PMCID: PMC4164851.

    Zheng Li
    Title Associate Professor, Genome Institute of Singapore, Visiting Professor, Sun Yat-sen University Cancer Center (2016.1-2019.1)

    Dr. Zheng Li is associate professor of Human Genetics Department at the Genome Institute of Singapore. Dr. Li received MD from the University of Newcastle in 2006, supported by the Overseas Research Students Awards Scheme. Dr. Li has extensive experience in the field of human genetics and related area of research, and has published 25 papers in Nature Genetics, American Journal of Human Genetics, etc.

    Research Interest(s)
    1. A common variant mapping toCACNA1A is associated with susceptibility to exfoliation syndrome. Aung T, Ozaki M, Mizoguchi T, Allingham RR, Li Z, Haripriya A, Nakano S, Uebe S, Harder JM, Chan AS, Lee MC, Burdon KP, Astakhov YS, Abu-Amero KK, Zenteno JC, Nilgün Y, Zarnowski T, Pakravan M, Safieh LA, Jia L, Wang YX, Williams S, PaoliD, Schlottmann PG, Huang L, Sim KS, Foo JN, Nakano M, Ikeda Y, Kumar RS, Ueno M, Manabe S, Hayashi K, Kazama S, Ideta R, Mori Y, Miyata K, Sugiyama K, HigashideT, Chihara E, Inoue K, Ishiko S, Yoshida A, Yanagi M, Kiuchi Y, Aihara M, Ohashi T, Sakurai T, Sugimoto T, Chuman H, Matsuda F, Yamashiro K, Gotoh N, Miyake M,Astakhov SY, Osman EA, Al-Obeidan SA, Owaidhah O, Al-Jasim L, Al Shahwan S,Fogarty RA, Leo P, Yetkin Y, Oğuz Ç, Kanavi MR, Beni AN, Yazdani S, Akopov EL,Toh KY, Howell GR, Orr AC, Goh Y, Meah WY, Peh SQ, Kosior-Jarecka E, Lukasik U,Krumbiegel M, Vithana EN, Wong TY, Liu Y, Koch AE, Challa P, Rautenbach RM,Mackey DA, Hewitt AW, Mitchell P, Wang JJ, Ziskind A, Carmichael T, Ramakrishnan R, Narendran K, Venkatesh R, Vijayan S, Zhao P, Chen X, Guadarrama-Vallejo D,Cheng CY, Perera SA, Husain R, Ho SL, Welge-Luessen UC, Mardin C,Schloetzer-Schrehardt U, Hillmer AM, Herms S, Moebus S, Nöthen MM, Weisschuh N,Shetty R, Ghosh A, Teo YY, Brown MA, Lischinsky I; Blue Mountains Eye Study GWAS Team; Wellcome Trust Case Control Consortium 2, Crowston JG, Coote M, Zhao B,Sang J, Zhang N, You Q, Vysochinskaya V, Founti P, Chatzikyriakidou A,Lambropoulos A, Anastasopoulos E, Coleman AL, Wilson MR, Rhee DJ, Kang JH,May-Bolchakova I, Heegaard S, Mori K, Alward WL, Jonas JB, Xu L, Liebmann JM,Chowbay B, Schaeffeler E, Schwab M, Lerner F, Wang N, Yang Z, Frezzotti P,Kinoshita S, Fingert JH, Inatani M, Tashiro K, Reis A, Edward DP, Pasquale LR,Kubota T, Wiggs JL, Pasutto F, Topouzis F, Dubina M, Craig JE, Yoshimura N,Sundaresan P, John SW, Ritch R, Hauser MA, Khor CC.. Nat Genet.2015 Apr;47(4):387-92.

    2. Common variants near ABCA1 and in PMM2 are associated with primary open-angleglaucoma. Dunstan SJ, Hue NT, Han B, Li Z, Tram TT, Sim KS, Parry CM, Chinh NT, Vinh H, Lan NP, Thieu NT, Vinh PV, Koirala S, Dongol S, Arjyal A, Karkey A, Shilpakar O, Dolecek C, Foo JN, Phuong le T, Lanh MN, Do T, Aung T, Hon do N, Teo YY, Hibberd ML, Anders KL, Okada Y, Raychaudhuri S, Simmons CP, Baker S, de Bakker PI,Basnyat B, Hien TT, Farrar JJ, Khor CC. Variation at HLA-DRB1 is associated with resistance to enteric fever. Nat Genet. 2014 Dec;46(12):1333-6. doi:10.1038/ng.3143. Epub 2014 Nov 10. PubMed PMID: 25383971.6: Chen Y, Lin Y, Vithana EN, Jia L, Zuo X, Wong TY, Chen LJ, Zhu X, Tam PO, GongB, Qian S, Li Z, Liu X, Mani B, Luo Q, Guzman C, Leung CK, Li X, Cao W, Yang Q,Tham CC, Cheng Y, Zhang X, Wang N, Aung T, Khor CC, Pang CP, Sun X, Yang Z Nat Genet. 2014 Oct;46(10):1115-9.

    3. “Recessive Mutations in KCNJ13, Encoding an Inwardly Rectifying Potassium Channel Subunit, Cause Leber Congenital Amaurosis.” Sergouniotis PI, Davidson AE, Mackay DS, Li Z, Yang X, Plagnol V, Moore AT, Webster AR. Am J Hum Genet. 2011 Jul 15;89(1):183-90.

    Khor Chiea Chuen
    Title Principle Investigator of Human Genetics, Genome Institute of Singapore, Visiting Professor, Sun Yat-sen University Cancer Center (2016.1-2019.1)

    1. 2009.6–2011.3
    Research Fellow
    Genome Institute of Singapore

    2. Research Scientist
    Genome Institute of Singapore

    3. Senior Research Scientist and Principal Investigator
    Genome Institute of Singapore

    4.  Group Leader and Senior Principal Investigator
    Genome Institute of Singapore
    Since 2015.4 


    Research Interest(s)

    Many a time, we observe (and sometimes even comment) that a friend's child bears a striking resemblance to his/her parent. This is a profound testimony to the contribution of hereditable elements which shape our being. We now go one little step further and ask: 'Are some of the diseases afflicting us linked, in one way or another, to our genetic makeup?"
    Although I qualified as a medical doctor, I realized that my calling was to pursue medical research in a full-time manner. My interest has always been to study the determinants which predispose otherwise healthy human beings to disease, and to see if the information so gathered can be used to help patients. Unfortunately, we do not fully understand how disease processes work. I enjoy conducting genetic studies because more often than not, the findings illuminate medical science, and have an opportunity to change clinical practise for the better in the long term.

    My laboratory practise spans many areas of human genetics studied across diverse human traits and disease conditions, with the long term goal of translating genetic findings into predictive medicine to improve healthcare in Singapore.



    1. Khor CC, Do T, Jia H, Nakano M, George R, Abu-Amero K, Duvesh R, Chen LJ, Li Z, Nongpiur ME, Perera SA, Qiao C, Wong HT, Sakai H, Barbosa de Melo M, Lee MC, Chan AS, Azhany Y, Dao TL, Ikeda Y, Perez-Grossmann RA, Zarnowski T, Day AC, Jonas JB, Tam PO, Tran TA, Ayub H, Akhtar F, Micheal S, Chew PT, Aljasim LA, Dada T, Luu TT, Awadalla MS, Kitnarong N, Wanichwecharungruang B, Aung YY, Mohamed-Noor J, Vijayan S, Sarangapani S, Husain R, Jap A, Baskaran M, Goh D, Su DH, Wang H, Yong VK, Yip LW, Trinh TB, Makornwattana M, Nguyen TT, Leuenberger EU, Park KH, Wiyogo WA, Kumar RS, Tello C, Kurimoto Y, Thapa SS, Pathanapitoon K, Salmon JF, Sohn YH, Fea A, Ozaki M, Lai JS, Tantisevi V, Khaing CC, Mizoguchi T, Nakano S, Kim CY, Tang G, Fan S, Wu R, Meng H, Nguyen TT, Tran TD, Ueno M, Martinez JM, Ramli N, Aung YM, Reyes RD, Vernon SA, Fang SK, Xie Z, Chen XY, Foo JN, Sim KS, Wong TT, Quek DT, Venkatesh R, Kavitha S, Krishnadas SR, Soumittra N, Shantha B, Lim BA, Ogle J, de Vasconcellos JP, Costa VP, Abe RY, de Souza BB, Sng CC, Aquino MC, Kosior-Jarecka E, Fong GB, Tamanaja VC, Fujita R, Jiang Y, Waseem N, Low S, Pham HN, Al-Shahwan S, Craven ER, Khan MI, Dada R, Mohanty K, Faiq MA, Hewitt AW, Burdon KP, Gan EH, Pru tthipongsit A, Patthanathamrongkasem T, Catacutan MA, Felarca IR, Liao CS, Rusmayani E, Istiantoro VW, Consolandi G, Pignata G, Lavia C, Rojanapongpun P, Mangkornkanokpong L, Chansangpetch S, Chan JC, Choy BN, Shum JW, Than HM, Oo KT, Han AT, Yong VH, Ng XY, Goh SR, Chong YF, Hibberd ML, Seielstad M, Png E, Dunstan SJ, Chau NV, Bei J, Zeng YX, Karkey A, Basnyat B, Pasutto F, Paoli D, Frezzotti P, Wang JJ, Mitchell P, Fingert JH, Allingham RR, Hauser MA, Lim ST, Chew SH, Ebstein RP, Sakuntabhai A, Park KH, Ahn J, Boland G, Snippe H, Stead R, Quino R, Zaw SN, Lukasik U, Shetty R, Zahari M, Bae HW, Oo NL, Kubota T, Manassakorn A, Ho WL, Dallorto L, Hwang YH, Kiire CA, Kuroda M, Djamal ZE, Peregrino JI, Ghosh A, Jeoung JW, Hoan TS, Srisamran N, Sandragasu T, Set SH, Doan VH, Bhattacharya SS, Ho CL, Tan DT, Sihota R, Loon SC, Mori K, Kinoshita S, Hollander AI, Qamar R, Wang YX, Teo YY, Tai ES, Hartleben-Matkin C, Lozano-Giral D, Saw SM, Cheng CY, Zenteno JC, Pang CP, Bui HT, Hee O, Craig JE, Edward DP, Yonahara M, Neto JM, Guevara-Fujita ML, Xu L, Ritch R, Liza-Sharmini AT, Wong TY, Al-Obeidan S, Do NH, Sundaresan P, Tham CC, Foster PJ, Vijaya L, Tashiro K, Vithana EN, Wang N, Aung T "Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma." Nat Genet 2016 May ; 48(5) : 556-62 Epub 2016 Apr 4 Abstract

    2. Cheng CY, Yamashiro K, Jia Chen L, Ahn J, Huang L, Huang L, Cheung CM, Miyake M, Cackett PD, Yeo IY, Laude A, Mathur R, Pang J, Sim KS, Koh AH, Chen P, Lee SY, Wong D, Chan CM, Loh BK, Sun Y, Davila S, Nakata I, Nakanishi H, Akagi-Kurashige Y, Gotoh N, Tsujikawa A, Matsuda F, Mori K, Yoneya S, Sakurada Y, Iijima H, Iida T, Honda S, Lai TY, Tam PO, Chen H, Tang S, Ding X, Wen F, Lu F, Zhang X, Shi Y, Zhao P, Zhao B, Sang J, Gong B, Dorajoo R, Yuan JM, Koh WP, van Dam RM, Friedlander Y, Lin Y, Hibberd ML, Foo JN, Wang N, Wong CH, Tan GS, Park SJ, Bhargava M, Gopal L, Naing T, Liao J, Guan Ong P, Mitchell P, Zhou P, Xie X, Liang J, Mei J, Jin X, Saw SM, Ozaki M, Mizoguchi T, Kurimoto Y, Woo SJ, Chung H, Yu HG, Shin JY, Park DH, Kim IT, Chang W, Sagong M, Lee SJ, Kim HW, Lee JE, Li Y, Liu J, Teo YY, Heng CK, Lim TH, Yang SK, Song K, Vithana EN, Aung T, Bei JX, Zeng YX, Tai ES, Li XX, Yang Z, Park KH, Pang CP, Yoshimura N, Yin Wong T, Khor CC "New loci and coding variants confer risk for age-related macular degeneration in East Asians." Nature Communications 2015 ; 6 : 6063 Abstract

    3. Aung T, Ozaki M, Mizoguchi T, Allingham RR, Li Z, Haripriya A, Nakano S, Uebe S, Harder JM, Chan AS, Lee MC, Burdon KP, Astakhov YS, Abu-Amero KK, Zenteno JC, Nilgün Y, Zarnowski T, Pakravan M, Safieh LA, Jia L, Wang YX, Williams S, Paoli D, Schlottmann PG, Huang L, Sim KS, Foo JN, Nakano M, Ikeda Y, Kumar RS, Ueno M, Manabe SI, Hayashi K, Kazama S, Ideta R, Mori Y, Miyata K, Sugiyama K, Higashide T, Chihara E, Inoue K, Ishiko S, Yoshida A, Yanagi M, Kiuchi Y, Aihara M, Ohashi T, Sakurai T, Sugimoto T, Chuman H, Matsuda F, Yamashiro K, Gotoh N, Miyake M, Astakhov SY, Osman EA, Al-Obeidan SA, Owaidhah O, Al-Jasim L, Shahwan SA, Fogarty RA, Leo P, Yetkin Y, Oğuz Ç, Kanavi MR, Beni AN, Yazdani S, Akopov EL, Toh KY, Howell GR, Orr AC, Goh Y, Meah WY, Peh SQ, Kosior-Jarecka E, Lukasik U, Krumbiegel M, Vithana EN, Wong TY, Liu Y, Koch AE, Challa P, Rautenbach RM, Mackey DA, Hewitt AW, Mitchell P, Wang JJ, Ziskind A, Carmichael T, Ramakrishnan R, Narendran K, Venkatesh R, Vijayan S, Zhao P, Chen X, Guadarrama-Vallejo D, Cheng CY, Perera SA, Husain R, Ho SL, Welge-Luessen UC, Mardin C, Schloetzer-Schrehardt U, Hillmer AM, Herms S, Moebus S, Nöthen MM, Weisschuh N, Shetty R, Ghosh A, Teo YY, Brown MA, Lischinsky I, Crowston JG, Coote M, Zhao B, Sang J, Zhang N, You Q, Vysochinskaya V, Founti P, Chatzikyriakidou A, Lambropoulos A, Anastasopoulos E, Coleman AL, Wilson MR, Rhee DJ, Kang JH, May-Bolchakova I, Heegaard S, Mori K, Alward WL, Jonas JB, Xu L, Liebmann JM, Chowbay B, Schaeffeler E, Schwab M, Lerner F, Wang N, Yang Z, Frezzotti P, Kinoshita S, Fingert JH, Inatani M, Tashiro K, Reis A, Edward DP, Pasquale LR, Kubota T, Wiggs JL, Pasutto F, Topouzis F, Dubina M, Craig JE, Yoshimura N, Sundaresan P, John SW, Ritch R, Hauser MA, Khor CC "A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome." Nature Genetics 2015 Feb 23 Abstract

    4. Dunstan SJ, Hue NT, Han B, Li Z, Tram TT, Sim KS, Parry CM, Chinh NT, Vinh H, Lan NP, Thieu NT, Vinh PV, Koirala S, Dongol S, Arjyal A, Karkey A, Shilpakar O, Dolecek C, Foo JN, Phuong LT, Lanh MN, Do T, Aung T, Hon DN, Teo YY, Hibberd ML, Anders KL, Okada Y, Raychaudhuri S, Simmons CP, Baker S, de Bakker PI, Basnyat B, Hien TT, Farrar JJ, Khor CC "Variation at HLA-DRB1 is associated with resistance to enteric fever." Nature Genetics 2014 Nov 10 Abstract

    5. Chen Y, Lin Y, Vithana EN, Jia L, Zuo X, Wong TY, Chen LJ, Zhu X, Tam PO, Gong B, Qian S, Li Z, Liu X, Mani B, Luo Q, Guzman C, Leung CK, Li X, Cao W, Yang Q, Tham CC, Cheng Y, Zhang X, Wang N, Aung T, Khor CC#, Pang CP#, Sun X#, Yang Z# "Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma." Nature Genetics 2014 Aug 31 #shared last authors Abstract

    6. Khor CC, Hibberd ML "Host-pathogen interactions revealed by human genome-wide surveys." Trends in Genetics 2012 Mar 22 Abstract

    7. Khor CC*, Davila S*, Breunis WB*, Lee YC, Shimizu C, Wright VJ, Yeung RS, Tan DE, Sim KS, Wang JJ, Wong TY, Pang J, Mitchell P, Cimaz R, Dahdah N, Cheung YF, Huang GY, Yang W, Park IS, Lee JK, Wu JY, Levin M, Burns JC, Burgner D, Kuijpers TW, Hibberd ML, on behalf of the Hong Kong-Shanghai, Korean, Taiwan, U.S. and International, Kawasaki Disease Genetics Consortiums. (* Joint first authors ) "Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease." Nature Genetics 2011 Nov 13 Epub 2011 Nov 13 Abstract

    8. Khor CC, Chau TN, Pang J, Davila S, Long HT, Ong RT, Dunstan SJ, Wills B, Farrar J, Van Tram T, Gan TT, Binh NT, Tri LT, Lien LB, Tuan NM, Tham NT, Lanh MN, Nguyet NM, Hieu NT, Van N Vinh Chau N, Thuy TT, Tan DE, Sakuntabhai A, Teo YY, Hibberd ML, Simmons CP "Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1." Nature Genetics 2011 Oct 16 Epub 2011 Oct 16 Abstract

    9. Khor CC*, Ramdas WD*, Vithana EN*, Cornes BK, Sim X, Tay WT, Saw SM, Zheng Y, Lavanya R, Wu R, Wang JJ, Mitchell P, Uitterlinden AG, Rivadeneira F, Teo YY, Chia KS, Seielstad M, Hibberd M, Vingerling JR, Klaver CC, Jansonius NM, Tai ES, Wong TY, van Duijn CM, Aung T * Joint first authors "Genome-wide association studies in Asians confirm the involvement of ATOH7 and TGFBR3, and further identify CARD10 as a novel locus influencing optic disc area." Human Molecular Genetics 2011 May 1 ; 20(9) : 1864-72 Epub 2011 Feb 9 Abstract

    10. Khor CC*#, Vannberg FO*, Chapman SJ*, Guo H*, Wong SH, Walley AJ, Vukcevic D, Rautanen A, Mills TC, Chang KC, Kam KM, Crampin AC, Ngwira B, Leung CC, Tam CM, Chan CY, Sung JJ, Yew WW, Toh KY, Tay SK, Kwiatkowski D, Lienhardt C, Hien TT, Day NP, Peshu N, Marsh K, Maitland K, Scott JA, Williams TN, Berkley JA, Floyd S, Tang NL, Fine PE, Goh DL, Hill AV * Joint first authors; # Corresponding author "CISH and susceptibility to infectious diseases." New England Journal of Medicine 2010 Jun 3 ; 362(22) : 2092-101 Epub 2010 May 19 Abstract

    Shicheng Yang
    Title CSO and Director of R&D Department, ZMKS International Cancer Therapy Biotechnologies Co, Ltd, Visiting Professor, Sun Yat-sen University Cancer Center (2015.1-2018.1)

    Dr. Yang is a well-established immunologist in the field of cancer immunotherapy with more than 20 years’ translational research and clinical trial experience. After obtaining his Ph.D. at Sun Yat-Sen University of Medical Sciences, Guangzhou, China, Dr. Yang had several rounds of postdoctoral training at some prestigious Institutes including Thomas Jefferson University and University of Pennsylvania.Before his current appointment at ZMKS International Cancer Therapy Biotechnologies Company, he had served as a Senior Research fellow at the Cellular Immunotherapy Section (National Cancer Institute/NIH) led by Dr. Rosenberg, Assistant Professor of Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center at Duke University, and VP Director of Biotherapeutics Department at YZY Biopharma Company. Dr. Yang has directed several R01 grants sponsored by National Institutes of Health (NIH), published more than 30 articles in peer-reviewed scientific journals, served as editors of many international journals, and delivered many lectures as invited speakers at institutions and international immunotherapy conferences. In recent years, Dr. Yang is focusing on translational research in the area of Cancer Immunotherapy, he is actively involved in several IND submissions and Phase I clinical trials.

    Research Interest(s)

    1. Yang, S et al. (2013) A cytokine-cocktail directly modulated the phenotype of DC-enriched anti-tumor T cells convey potent anti-tumor activities in a murine tumor model. Cancer Immunol Immunother. 62(11):1649-62.

    2. Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, and Morgan RA. (2013) Modulating the differentiation status of ex vivo cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother. 62:727–736

    3. Yang S, Karne, NK, Goff, SL, Black, MA, Xu, H, Bischof, D, Cornetta, K, Rosenberg, SA, Morgan, RA, and Feldman, SA. (2012) A Simple and Effective Method to Generate Lentiviral Vectors for ex Vivo Gene Delivery to Mature Human Peripheral Blood Lymphocytes. Hum Gene Ther Methods. 23(2): 73–83

    4. Yang S, Liu F, Rosenberg SA, Morgan RA, et al. (2011) The Shedding of CD62L (L-Selectin) Regulates the Acquisition of Lytic Activity in Human Tumor Reactive T Lymphocytes. PloS ONE.

    5. Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, et al. (2011)  In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 60(5):739-49

    6. Yang S, Dudley ME, Rosenberg SA, Morgan RA (2010) A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother 33: 648-658.

    7. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Yang S, et al. (2010)  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood.  117(3):808-14.

    8. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, et al. (2009) A herceptin- based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183: 5563-5574.

    9. Yang S, Rosenberg SA, Morgan RA (2008) Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J Immunother 31: 830-839.

    10.Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15: 1411-1423.

    Qiang Pan
    Title Professor, Karolinska Institutet, Visiting Professor, Sun Yat-sen University Cacner Center (2015.3-2017.3)

    Prof. Qiang Pan-Hammarström currently is professor of clinical immunology, PhD supervisor at Karolinska Institutet, and visiting professor of Sun Yat-sen University Cacner Center and Tianjin Medical University Cancer Institute and Hospital. She has published numerous papers in top SCI journals including Cell,Nature Genetics, Nature Immunology, Nature Biotechnology, Journal of Experimental Medicine,PNAS, Blood, etc.

    Research Interest(s)

    Prof. Qiang Pan-Hammarström focuses on two main areas of research: Immunogenetics and Cancer Genetics.


    1. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas.Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S, et al Nat Commun 2015;6():10131

    2. Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.Björkman A, Qvist P, Du L, Bartish M, Zaravinos A, Georgiou K, et al Proc. Natl. Acad. Sci. U.S.A. 2015 Feb;112(7):2157-62

    3. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.Qian J, Wang Q, Dose M, Pruett N, Kieffer-Kwon K, Resch W, et al. Cell 2014 Dec;159(7):1524-37

    4. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese Miranda N, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, et al Blood 2014 Oct;124(16):2544-53

    5. A regulatory role for the cohesin loader NIPBL in nonhomologous end joining during immunoglobulin class switch recombination.Enervald E, Du L, Visnes T, Björkman A, Lindgren E, Wincent J, et al J. Exp. Med. 2013 Nov;210(12):2503-13

    6. New facets of antibody deficiencies.Liadaki K, Sun J, Hammarström L, Pan-Hammarström Q Curr. Opin. Immunol. 2013 Oct;25(5):629-38

    7. DNA repair genes are selectively mutated in diffuse large B cell Miranda N, Peng R, Georgiou K, Wu C, Falk Sörqvist E, Berglund M, et al J. Exp. Med. 2013 Aug;210(9):1729-42

    8. Nurture your scientific curiosity early in your research career. Jagodic M, Stridh P, Gad A, Paine A, Udekwu K, Sjöholm L, et al Nat. Genet. 2013 Feb;45(2):116-8

    9. Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. Du L, Peng R, Björkman A, Filipe de Miranda N, Rosner C, Kotnis A, et alJ. Exp. Med. 2012 Feb;209(2):291-305

    Kai-Wen Huang
    Title Attending Physician and Associate Professor, College of Medicine, Taiwan University, Visiting Professor, Sun Yat-sen University Cancer Center

    Prof. Kai-Wen Huang currently serves as Director of the Minimally Invasive Cancer Therapy Center of Taiwan University. His work focuses on hepatopancreaticobiliary surgery, laparoscopic oncology, surgical oncology and tumor ablation therapy.

    Research Interest(s)

    1.Kai-Wen Huang, Shieh-Yueh Yang, Yu-Wei Hong, Jen-Jie Chieh, Che-Chuan Yang, Herng-Er Horng, Chau-Chung Wu, Chin-Yih Hong, Hong-Chang Yang*. Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles. International Journal of Nanomedicine. 2012. Apr;7:1991–1996.

    2. Hao-Tien Wang, Hsin-I Lee, Jih-Huong Guo, Shih-Hui Chen, Zhe-Kang Liao, Kai-Wen Huang, Pao-Ling Torng, Lih-Hwa Hwang*. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules. International Journal of Cancer. 012.Jun;130(12):2892–2902.

    3. K.-W. Huang, H.-H. Chen, H.-C. Yang, H.-E. Horng*, S.-H. Liao, J.-J. Chieh and S.Y. Yang. Use of a high-T-c SQUID-based nuclear magnetic resonance spectrometer in magnetically unshielded environments to discriminate tumors in rats, by characterizing the longitudinal relaxation rate. Journal of Instrumentation. 2012. Jun; 7: P06005.

    4. Kai-Wen Huang, Jen-Jie Chieh*, Herng-Er Horng *, Chin-Yih Hong , Hong-Chang Yang . Characteristics of magnetic labeling on liver tumors with anti-alpha-fetoprotein-mediated Fe3O4 magnetic nanoparticles. International Journal of Nanomedicine. 2012.June;7:2987-2996.

    5. Kai-Wen Huang, Hsin-Hsien Chen, Hong-Chang Yang*, Herng-Er Horng*, Shu-Hsien Liao, Shieh Yueh Yang, Jen-Jie Chieh, Li-Ming Wang. Discriminating Hepatocellular Carcinoma in Rats Using a High-Tc SQUID Detected Nuclear Resonance Spectrometer in a Magnetic Shielding Box. PLoS ONE.2012. October;7(10): e47057

    6. S.Y. Yang, J.J. Chieh, C.C. Yang, S.H. Liao, H.H. Chen, H.E. Horng, H.C. Yang, C.Y. Hong, M.J. Chiu, T.F. Chen, K.W. Huang*, C.C. Wu. Clinic Applications in Assaying Ultra-Low-Concentration Bio-Markers Using HTS SQUID-Based AC Magnetosusceptometer. IEEE TRANSACTIONS ON APPLIED SUPERCONDUCTIVITY. 2013 June;23(3):1600604

    7. Hsin-Hsien Chen, Kai-Wen Huang*, Hong-Chang Yang, Herng-Er Horng, and Shu-Hsien Liao. Optimization of the detection coil of high-Tc superconducting quantum interference device-based nuclear magnetic resonance for discriminating a minimum amount of liver tumor of rats in microtesla fields. Journal of Applied Physics.2013 August;114(6), 064701

    8. Kai-Wen Huang, Jen-Jie Chieh*, In-Tsang Lin, Herng-Er Horng*, Hong-Chang Yang and Chin-Yih Hong. Anti-CEA-functionalized superparamagnetic iron oxide nanoparticles for examining colorectal tumors in vivo. Nanoscale Research Letters. 2013 Oct ;8(1):413.

    9. Liang P, Huang K*. The reappraisal of Batson’s theory by isolated para-vertebral metastasis of hepatocellular carcinoma. PeerJ PrePrints. 2014 Jan; 2:e212v1

    10. V. Reebye, P. Sætrom, P.J. Mintz, K.W. Huang, P. Swiderski, L. Peng, C. Liu, X.X. Liu, S. Jensen, D. Zacharoulis, N. Kostomitsopoulos, N. Kasahara, J.P. Nicholls, L.R. Jiao, M. Pai, M. Mizandari, T. Chikovani, M.M. Emara, A.Haoudi, D.A. Tomalia, J.J. Rossi, N.A. Habib*, D.R. Spalding. A novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology. 2014 Jan;59(1):216-27. 并列第一作者.

    11. K. W. Huang, S. Y. Yang, H. E. Horng, J. J. Chieh, H. H. Chen, C. C. Wu, J. H. Chen, I.T. Lin, C. C. Yang, H.C.Yang. Time-Evolution Contrast of Target MRI Using High-Stability Antibody Functionalized Magnetic Nanoparticles: An Animal Model. Journal of Nanomaterials. 2014 August; 2014, Article ID 351848, 7 pages.

    12. Po-Chin Liang, Hong-Shiee Lai, Tiffany Ting-Fang Shih, Chih-Horng Wu and Kai-Wen Huang*. The pilot experience upon surgical ablation of large liver tumor by microwave system with tissue permittivity feedback control mechanism. BMC Surgery. 2014. October;14:82.

    13. P.-C. Liang, H.-S. Lai, T.T.-F. Shih, C.-H. Wu, K.-W. Huang*. Initial institutional experience of uncooled single-antenna microwave ablation for large hepatocellular carcinoma. Clinical Radiology. 2015.

    14. Kai-Wen Huang, Jen-Jie Chieh*, Jin-Cheng Shi, Ming-Hsien Chiang. Assaying Carcinoembryonic Antigens by Normalized Saturation Magnetization. Nanoscale Research Letters. 2015. JUL; 10:277

    Zhongxing Liao
    Title Professor in MD Anderson Cancer Center, Visiting Professor of SYSUCC (October 2015 – October 2018)

    Prof. Zhongxing Liao is the Professor of Radiation Oncology and the Deputy Department Chair of Radiation Oncology in MD Anderson Cancer Center.

    Medical School
    Hunan Medical University
    Clinical Internship:
    The University of Kansas School of Medicine-Wichita
    Clinical Residency:
    The University of Texas MD Anderson Cancer Center
    Clinical Fellowship:
    The University of Texas MD Anderson Cancer Center

    American College of Physician Executives (Management)
    Hunan Tumor Hospital & Institution (Radiation Oncology Residency)
    Rice University, Texas Medical Center (Executive Education Course: Strategy for Value-Based Healthcare Delivery)
    The University of Texas MD Anderson Cancer Center (Faculty Leadership Academy)
    The University of Texas MD Anderson Cancer Center (Faculty Development)
    University of Texas MD Anderson Cancer Center (Clinical Safety and Effectiveness Program)
    Research Fellowship:
    The University of Texas MD Anderson Cancer Center

    Board Certifications
    American Board of Radiology - Radiation Oncology
    Kansas State Board of Healing Arts
    Texas Medical License

    Research Interest(s)

    Her research interests focus on improving the therapeutic ratio of radiation therapy for thoracic malignancies through translational research. More specifically, she is seeking to improve the efficacy and reduce the toxicity of chemoradiation therapy for lung and esophageal cancers by using molecular targeting strategies; by using advanced radiation delivery technologies; by generating and using models for predicting risks of normal tissue toxicity; by reducing that toxicity with adaptive modification of radiation parameters based on biomarkers such as SNPs and serum levels of inflammatory cytokines, by reducing the symptom burden and improving patients quality of life using integrative medicine, and ultimately, by developing strategies to practice highly personalized treatments.


    1. Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao Z, Komaki R, Ang KK, Milas L. Epidermal growth factor receptor as a target to improve treatment of lung cancer., Clinical Lung Cancer, 5:2004

    2. Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao Z, Komaki R, Ang KK, Milas L. Epidermal growth factor receptor as a target to improve treatment of lung cancer., Clin lung cancer, 5:2005

    3. Brooks C, Starkschall G, Famiglietti R, Cox J, Frank S, Komaki R, Liao Z, Stevens C, Forster K. Heterogeneous planning for homogeneous protocols., Medical Dosimetry, 29:2004

    4. Burnett SS, Starkschalla G, Stevens CW, Liao Z. A deformable-model approach to semi-automatic segmentation of CT images demonstrated by application to the spinal canal., Med Phys, 31:2004

    5. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy., Clin Cancer Res, 11:2005

    6. Cox JD, Schechter NR, Lee AK, Forster K, Stevens CW, Ang K-K, Komaki R, Liao Z, Milas L. Uncertainties in physical and biological targeting with radiation therapy., Rays, 28:2003

    7. Forster KM, Smythe WR, Starkschall G, Liao Z, Takanaka T, Kelly JF, Vaporciyan A, Ahamad A, Dong L, Salehpour M, Komaki R, Stevens CW. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation., Int J Radiat Oncol Biol Phys, 55:2003

    8. Frank SJ, Forster KM, Stevens CW, Cox JD, Komaki R, Liao Z, Tucker S, Wang X, Steadham RE, Brooks C, Starkschall G. Treatment planning for lung cancer: traditional homogeneous point dose prescription compared with heterogeneity-corrected dose-volume prescription, Int J Radiat Oncol Biol Phys, 56:2003

    9. Gopal R, Starkschall G, Tucker SL, Cox JD, Liao Z, Hanus M, Kelly JF, Stevens CW, Komaki R. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer., Int J Radiat Oncol Biol Phys, 56:2003

    10. Gopal R, Tucker SL, Komaki R, Liao Z, Forster KM, Stevens C, Kelly JF, Starkschall G. The relationship between local dose and loss of function for irradiated lung., Int J Radiat Oncol Biol Phys, 56:2003

    Peter J. Hewett
    Title Head of the Colorectal Surgical Unit at the Queen Elizabeth Hospital and a Clinical Professor of Surgery at the University of Adelaide, Visiting Professor of SYSUCC (May 2015 – May 2018)

    Professor Peter Hewett is a specialist colorectal surgeon with over 25 years clinical experience. Peter is head of the Colorectal Surgical Unit at The Queen Elizabeth Hospital and a Clinical Professor of Surgery at the University of Adelaide. He has extensive experience in colonoscopy, major colonic and rectal resection for cancer and other conditions, Peter offers specialised treatment of anorectal problems including haemorrhoids and fistula. He has extensive experience in the treatment of faecal incontinence by Sacral Nerve Stimulation. Peter's other major clinical interest is the treatment of conditions such as Pseudomyxoma Peritoneii and abdominal mesothelioma via Peritonectomy and Heated Intraperitoneal Chemotherapy (HIPEC). This procedure is done at The Queen Elizabeth Hospital.

    Peter has received numerous research grants including NH&MRC grants and has supervised a number of postgraduate students for higher degrees. He has created and teaches a Masters Course in Minimally Invasive Surgery through the University of Adelaide. He is the author of over 100 peer reviewed published articles on a variety of topics.

    Research Interest(s)

    1. Michael G A Norwood Jacqueline H Stephens1, Peter J Hewett. The nursing and financial implications of laparoscopic colorectal surgery: data from a randomised controlled trial. Colorectal Disease. 13(11):1303-7, 2011 Nov.

    2. Hewett, Peter J. FRACS; Frizelle, Frank MBChB, MMedSc, FRACS, FACS Letter. Reply; Does Laparoscopic Colectomy Have a Higher Intraoperative Complication Rate Than Open Colectomy? Annals of Surgery: March 2010 - Volume 251 - Issue 3 - p 578

    3. Andrew Strickland, Katherine Fairhurst, Chris Lauder, Peter Hewett and Guy Maddern Development of an ex vivo simulated training model for laparoscopic liver resection. Surgical Endoscopy: Accepted for publication.

    4. Howard K, Salkeld G, Pignone M, Hewett P, Cheung P, Olsen J, Clapton W, Roberts-Thomson IC.  Preferences for CT colonography and colonoscopy as diagnostic tests for colorectal cancer: A discrete choice experiment. Value in Health ; 2011 (Accepted July 4 2011)

    5. Stephens JH. Hewett PJ. Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome. ANZ Journal of Surgery. 82(6):420-7, 2012 Jun.

    6. Sturm L. Dawson D. Vaughan R. Hewett P. Hill AG. Graham JC. Maddern GJ. Effects of fatigue on surgeon performance and surgical outcomes: a systematic review. ANZ Journal of Surgery. 81(7-8):502-9, 2011 Jul-Aug.

    7. Allardyce RA. Bagshaw PF. Frampton CM. Frizelle FA. Hewett PJ. Rieger NA. Smith JS. Solomon MJ. Stevenson AR. Ethical issues with the disclosure of surgical trial short-term data. ANZ Journal of Surgery. 81(3):125-31, 2011 Mar.

    8. A randomized crossover trial examining low- versus high-fidelity simulation in basic laparoscopic skills training. Tan SC, Marlow N, Field J, Altree M, Babidge W, Hewett P, Maddern GJ Surg Endosc. 2012 Nov;26(11):3207-14.

    9. Long-term outcomes of the australasian randomized clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer: the Australasian Laparoscopic Colon Cancer Study trial. Bagshaw PF, Allardyce RA, Frampton CM, Frizelle FA, Hewett PJ, McMurrick PJ, Rieger NA, Smith JS, Solomon MJ, Stevenson AR; Australasian Laparoscopic Colon Cancer Study Group. Ann Surg. 2012 Dec;256(6):915

    10. Warm-up before laparoscopic surgery is not essential. Weston MK, Stephens JH, Schafer A, Hewett PJ. ANZ J Surg. 2012 Nov 22

    11. Effect of pre-operative 2-D animation information on peri-operative anxiety and knowledge retention in patients undergoing bowel surgery: A randomised pilot study. Tou S, Tou W, Mah D, Karatassas A, Hewett P.  Colorectal Dis. 2013 Jan 26

    12. Effect of fatigue on laparoscopic skills: a comparative historical cohort study. Daruwalla J, Marlow N, Field J, Altree M, Babidge W, Hewett P, Maddern GJ. ANZ J Surg. 2013 Jan 27.

    13. A Systematic Review of Surgical Skills Transfer After Simulation-Based Training: Laparoscopic Cholecystectomy and Endoscopy. Susan R Dawe, John A Windsor, Joris A J L Broeders, Patrick C Cregan, Peter J Hewett, Guy J Maddern. Annals of surgery 10/2013;

    14. A Randomized Double-Blind Clinical Trial of a Continuous 96-Hour Levobupivacaine Infiltration After Open or Laparoscopic Colorectal Surgery for Postoperative Pain Management-Including Clinically Important Changes in Protein Binding. Sumithra Krishnan, Raymond G Morris, Peter J Hewett, John Field,Alex Karatassas, Samson Tou, Ian S Westley, Fiona A Wicks, Julie A Tonkin. Therapeutic drug monitoring 10/2013; ·

    15. Construct, Concurrent, and Content Validity of the eoSim Laparoscopic Simulator. Iain A M Hennessey, Peter Hewett. Journal of Laparoendoscopic & Advanced Surgical Techniques 08/2013;·

    16. Laparoscopic skills acquisition: a study of simulation and traditional training. Nicholas Marlow, Meryl Altree, Wendy Babidge, John Field, Peter Hewett, Guy J Maddern. ANZ Journal of Surgery 06/2013;

    17. Troubleshooting in laparoscopy- how to treat “poor visibility”Soeren Torge Mees1,2, M.D.; Neil Bhardwaj1,3, M.D.; Ivan Sini4, M.D.; Martin Varley1, M.D.; Guy Maddern1, M.D.; Peter Hewett1, M.D.; Accepted for publication August 2013 ANZ J Surgery

    Martin R. Weiser
    Title Professor of Memorial Sloan-Kettering Cancer Center, Visiting Professor of SYSUCC (July 2015 – June 2018)

    In 1991 Prof. Martin R. Weiser received his Doctoral Degree in Medicine Pritzker Medical School, University of Michigan and in 1998 he was named the Fellow of American College of Surgeon. He became the assistant professor in Memorial Sloan-Kettering Cancer Center in 2001 and later worked as the assistant professor in Cornell Medical College. Since 2013, he has been the professor in Memorial Sloan-Kettering Cancer Center.

    Research Interest(s)
    Steven C. Campbell
    Title Professor of Surgery at Cleveland Clinic, Visiting Professor in SYSUCC (June 2014 – June 2017)

    Steven Campbell, MD, PhD, is Professor of Surgery, Residency Program Director, and a member of the Section of Urologic Oncology in the Glickman Urological and Kidney Institute at Cleveland Clinic.
    He obtained his medical degrees at the University of Chicago and completed his urology residency at Cleveland Clinic (1989-1995), followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center (1995-1996).

    Dr. Campbell’s primary interests include renal cell carcinoma, bladder cancer, prostate cancer, treatment-related osteoporosis and tumor angiogenesis.  His background also includes American Foundation for Urologic Disease (AFUD) and Kimmel Research Scholarship awards, and he is a former member of the American Board of Urology Examination Committee. Dr. Campbell is currently on the educational board for AFUD and the medical advisory board for the Kidney Cancer Association.

    Professional Highlights
    Vice Chairman Urology, Center for Urologic Oncology, 2010
    Residency Program Director, Cleveland Clinic, 2006-Present
    Chief of Urology, Edward Hines Jr. VA Hospital, Chicago, 2001-2005
    American Urologic Association, Boards Examination Committee, 1999-2003
    American Joint Committee on Cancer, Committee for Staging Urologic Cancers, 2006-2010
    Society of Urologic Oncology, Examination Committee

    Research Interest(s)

    1. Demirjian S, Lane BR, Derweesh IH, Takagi T, Fergany A, Campbell SC.  Chronic Kidney Disease Due to Surgical Removal of Nephrons: Relative Rates of Progression and Survival.  J Urol. doi: 10.1016/j.juro.2014.04.016.

    2. Mir MC, Takagi T, Campbell RA, Sharma N, Remer EM, Li J, Demirjian S, Stein R, Kaouk J, Campbell SC. Poorly Functioning Kidneys Recover from Ischemia after Partial Nephrectomy as Well as Strongly Functioning Kidneys.  J Urol.  doi: 10.1016/j.juro.2014.03.036.

    3. Takagi T, Mir MC, Campbell RA, Sharma N, Remer EM, Li J, Demirjian S, Kaouk JH, Campbell SC.  Predictors of Precision of Excision and Reconstruction in Partial Nephrectomy.  J Urol. doi: 10.1016/j.juro.2013.12.035.

    4. Goenka AH, Remer EM, Smith AD, Obuchowski NA, Klink J, Campbell SC.  Development of a clinical prediction model for assessment of malignancy risk in Bosniak III renal lesions.  Urology. 2013 Sep;82(3):630-5.

    5. Ching, CB, Lane B, Campbell SC, Li J, Fergany A: Five and ten year follow-up of open partial nephrectomy in a solitary kidney.  J Urology, 190: 470-474, 2013.

    6. Mir CM, Campbell RA, Sharma N, Remer EM, Simmons M, Li J, Demirjian S, Kaouk J, Campbell SC: Parenchymal Volume Preservation and Ischemia During Partial Nephrectomy: Functional and Volumetric Analysis. UROLOGY, 82:263-9, 2013.

    Patrick Ma
    Title Associate Professor of West Virginia University, Visiting Professor of SYSUCC (September 2014 – August 2017)

    Dr. Patrick Ma is a medical oncologist in Morgantown, West Virginia and is affiliated with West Virginia University Hospitals. He received his medical degree from University of Toronto Faculty of Medicine and has been in practice for more than 20 years. Since 2014, he has joint West Virginia University and now he is the Co-Leader of the Sara Crile Allen & James Frederick Allen Comprehensive Lung Cancer Program.

    Research Interest(s)

    Lung cancer


    1.  Ma PC-C, Siu C-H.  A pharmacologically distinct cAMP receptor is responsible for the regulation of gp80 expression in Dictyostelium discoideum.  Mol. Cell. Biol. 10: 3297-3306, 1990.

    2.  Ma PC, Chan, LKC, Huynh X. Intention to relocate to the United States: Analysis of motivational factors influencing family medicine residents. Can. Fam.Physician 43:1533-1539, 1997.

    3.  Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c -Kit in small cell lung cancer. Cancer Research 62:6304-6311, 2002.

    4.  Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.  Clinical Cancer Research 8:620-627, 2002.

    5.  Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R. Activated HGF/c-Met signaling pathways is modulated by PI3-K.  J. Cell. Mol. Med.  6:539-553, 2002.

    6. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.  Cytokine & Growth Factor Reviews 13:41-59, 2002.

    7.  Jafri N, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyro sine kinases in small cell lung cancer (Review).  J Environ Pathol Tox Oncol 22:147-165, 2003.

    8.  Ma PC, Blaskowsky L, Bharti A, Bruno A, Ladanyi A. Skarin AT, Chen LB, Salgia R. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.  Anticancer Res 23(1A):49-62, 2003.

    9.  Ma PC, Maulik G, Christensen J, Salgia R.  c-Met: structure, functions and potential for therapeutic inhibition. (Review).  Cancer and Metastasis Review 22:309-325, 2003.

    10.  Kijima T, Maulik G, Ma PC, Salgia R.  Fibronectin enhances viability and alters cytoskeletal functions with effects on the phosphatidylinositol 3-kinase pathway in small cell lung cancer.  J. Cell. Mol. Med. 7:157-164, 2003. 

    11.  Sattler M, Pride YB, Ma P, Maulik G, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen J, Salgia R. A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase oncogene.  Cancer Research 63:5462–5469, 2003.

    12.  Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. c -MET mutational and functional analysis in small cell lung cancer: Novel mutations in the juxtamembrane domain.  Cancer Research63:6272-6281, 2003.

    13.  Bharti A, Ma PC, Maulik G, Singh R, Skarin AT, Khan E, Salgia R.  Haptoglobin -subunit and hepatocyte growth factor can potentially serve as serum tumor markers in small cell lung cancer. Anticancer Research 24:1031-1038, 2004.

    14.  Ma PC, Salgia R. Novel targets for therapeutic agents in SCLC (Review).  J National Comprehensive Cancer Network 2:165-172, 2004.

    15.  Surawska H, Ma PC, Salgia R.  The role of ephrins and Eph receptors in cancer. (Review), Cytokine & Growth Factor Reviews 15:419-433, 2004.


    Luhua Wang
    Title Professor of Lymphoma/Myeloma at MD Anderson Cancer Center, Visiting Professor of SYSUCC (October 2013 – October 2016)

    Prof. Luhua Wang is the Professor of Lymphoma/Myeloma in the Department of Stem Cell Transplantation and Cellular Therapy. He is also the founding and current Director of Lymphoma Program of Excellence and the Co-Director of Clinical Investigation and Translational Research.

    Medical Schools Education
    Beijing Medical University
    Shandong Medical University

    Dept. of Internal Medicine, The University of Michigan Hospitals (Internship)
    National Heart, Lung and Blood Institute, NIH (Visiting Associate)
    National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), NIH (Visiting Fellow (Recipient of Fogarty International Fellowship Award))
    The University of Texas MD Anderson Cancer Center (Medical Oncology/Hematology Fellow)
    Yale-Norwalk Hospital (Chief Medical Resident)
    Yale-Norwalk Hospital (Residency)

    Board Certifications
    American Board of Internal Medicine, Internal Medicine
    American Board of Internal Medicine, Medical Oncology

    Research Interest(s)

    1. Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Gardner JD, Jensen RT. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity., J Biol Chem, 264(25:1989

    2. Coy DH, Wang LH, Jensen RT. Bombesin agonists, partial agonists and antagonists-unexpected biological profiles among medicinally interesting analogues., Actualities de Chimie Therapeutique, Dix-Huiteme Serie (26 mes Recontes Interionales de Chimie Therapeutique, Montpellier France, 1990

    3. Rowley WH, Sato S, Huang SC, Collado-Escobar DM, Beaven MA, Wang LH, Martinez J, Gardner JD, Jensen RT. Cholecystokinin-induced formation of inositol phosphates in pancreatic acini., Am J Physiol, 259:1990

    4. Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, Frucht H, Haffar BM, Jensen RT. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists., J Biol Chem, 265(26:1990

    5. Wang LH, Coy DH, Taylor JE, Jiang NY, Kim SH, Moreau JP, Huang SC, Mantey SA, Frucht H, Jensen RT. Desmethionine alkylamide bombesin analogues: A new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells., Biochemistry, 29(3):1990

    6. Coy DH, Taylor JE, Jiang NY, Wang LH, Huang SC, Qian JM, Moreau JP, Jensen RT. Developing receptor antagonists of neuropeptides-the bombesin/GRP and substance P systems. Peptides., Neuropeptides and Their Receptors, Alfred Benzon Symposium 29, 29:1990
    von Schrenck T, Wang LH, Coy DH, Villanueva ML, Mantey S, Jensen RT. Potent bombesin receptor antagonists distinguish receptor subtypes., Am J Physiol, 259:1990

    7. Coy D, Wang LH, Jiang NY, Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells., Eur J Pharmacol, 190:1990

    8. Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Jensen RT. Short-chain bombesin receptor antagonists with IC50's for cellular secretion and growth approaching the picomolar region peptides., Proceedings of the 11th American Peptide Symposium Escom Science Publishers, 1990

    9. Sawyer TK, Jensen RT, Moran TH, Wang LH, Coy DH, Staples DG, DeVaux AE, Bradford VS. Structure activity relationships of cholecytokinin: Tyr[SO3H]: Substitutions Peptides., Chemistry, Structure and Biology, 1990

    Lawrence S. Young
    Title Pro-Vice Chancellor at University of Warwick, Visiting Professor of SYSUCC (April 2014 – March 2019)

    Prof. Lawrence S. Young now is the Pro-Vice Chancellor (Academic Planning and Resources) at University of Warwick. In the year 2008 – 2012, he was the vice chancellor of the University of Birmingham. Prof. Lawrence Young has been studying tumor virology for years. His works focus on EBV virus, HPV virus, oncogene and immunotherapy. He has published more than 220 research papers in these fields. His researches were published in Nature Revs. Cancer, Lancet and New Eng. J. Med.

    Research Interest(s)

    1. Young, Lawrence S. 2015. Pathogens best paper awards for 2015. Pathogens, 4 (2), pp. 387-389

    2. Palser, Anne L., Grayson, Nicholas E., White, Robert E., Corton, Craig, Correia, Samantha, Ba abdullah, Mohammed M., Watson, Simon J., Cotten, Matthew, Arrand, J. R. (John R.), Murray, Paul? (Paul G.)?, Allday, Martin J., Rickinson, Alan, Young, Lawrence S., Farrell, Paul J., Kellam, Paul, Longnecker, R. M.. 2015. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. Journal of Virology, Volume 89 (Number 10), pp. 5222-5237

    3. Elmetwali, Taha, Young, Lawrence S., Palmer, Daniel H.. 2014. Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-?B activation via a negative feedback loop. Cell Death and Disease, Volume 5 (Number 5)

    4. Hu, Chunfang, Wei, Wenbin, Chen, Xiaoyi, Woodman, Ciaran B. J., Yao, Yunhong, Nicholls, J. M. (John M.), Joab, Irà¨ne, Sihota, Sim K., Shao, Jian-Yong, Derkaoui, K. Dalia, Amari, Aicha, Maloney, Stephanie L., Bell, Andrew I., Murray, Paul G., Dawson, Christopher W., Young, Lawrence S., Arrand, J. R. (John R.). 2012. A global view of the oncogenic landscape in nasopharyngeal carcinoma : an integrated analysis at the genetic and expression levels. PLoS One, Vol.7 (No.7)

    5. Leonard, S. M., Wei, W., Collins, S. I., Pereira, M., Diyaf, A., Constandinou-Williams, C., Young, Lawrence S., Roberts, S., Woodman, Ciaran B. J.. 2012. Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis, Vol.33 (No.7), pp. 1286-1293

    6. Dawson, Christopher W., Port, Rebecca J., Young, Lawrence S.. 2012. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Seminars in Cancer Biology, Vol.22 (No.2), pp. 144-153

    7. Sivachandran, N., Dawson, C. W., Young, Lawrence S., Liu, F.-F., Middeldorp, J., Frappier, L.. 2012. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma. Journal of Virology, Vol.86 (No.1), pp. 60-68

    8. Steele, J. C., Rao, A., Marsden, J. R., Armstrong, C. J., Berhane, S., Billingham, L. J., Graham, N., Roberts, C., Ryan, G., Uppal, H., Walker, C., Young, Lawrence S., Steven, N. M.. 2011. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Therapy, Vol.18 (No.6), pp. 584-593

    9. Ma, Y. T., Collins, S. I., Young, Lawrence S., Murray, P. G., Woodman, Ciaran B. J.. 2011. Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. British Journal of Cancer, Vol.104 (No.9), pp. 1500-1504

    Jiping Wang
    Title Assistant Professor of Surgery at Harvard Medical School, Visiting Professor of SYSUCC (Sep 2014 – August 2017)

    Dr. Wang is a surgical oncologist in the Division of Surgical Oncology at Brigham and Women’s Hospital and the Gastrointestinal Cancer Treatment Center at Dana-Farber Cancer Institute. His clinical interest is gastrointestinal cancer surgery.

    Dr. Wang’s academic education includes medical education at Henan Medical University, and PhD in Biostatistics from University of Pittsburgh.

    Dr. Wang has been involved in cancer research for more than ten years. He had five years experience in designing, conducting and reporting phase III clinical trials at National Adjuvant Breast and Bowel Project (NSABP). His research regarding prognostic factor and cancer staging received three awards from American Society of Clinical Oncology foundation and one grant support from American Medical Association.

    Research Interest(s)

    Minimally invasive cancer surgery, Gastrointestinal malignancies including liver cancer, Colorectal cancer liver metastasis, Pancreatic, gastric, colorectal cancer and neuroendocrine tumor, Sarcoma


    1. Raghavendran, K., Wang, J., Belber, C., Brunton, K.., Berbary, E., Burke, MS., and Haas, CE., Predictive Value of Sputum Gram Stain For The Determination of appropriate Antibiotic Therapy in VAP, Journal of Trauma-Injury Infection & Critical Care. 2007;62(6):1377-1383

    2. Merg, A., Wirtzfeld, D.W., Wang, J,, Cheney, R., Dunn, KB. and Rajput, A. Viability of endoscopic and excisional treatment of early rectal carcinoids, Journal of Gastrointestinal Surgery. 2007;11:893-7

    3. Cherr, G.S., Wang, J., Zimmerman, P.M., Dosluoglu, H.H., Depression is associated with worse patency and recurrent leg symptoms after lower extremity revascularization, J Vasc Surg. 2007;45:744-50.

    4. Vasquez, MA., Wang, J., Mahathanaruk, M., Dosluoglu, HH., Buczkowski, G., Venous Clinical Severity Scores and RF Saphenous Vein Ablation in 580 Limbs, J Vasc Surg. 2007;45:1008-1014.

    5. Wang, J, Hassett, J, Dayton, M. and Kulaylat, M. The prognostic superiority of log odds of lymph nodes in stage III colon cancer, Journal of Gastrointestinal Surgery.2008;12(10):1790-1796

    6. Wang, J., Hassett, J., Dayton, M. and Kulaylat, M., Lymph node ratio: the role in node positive colon cancer staging, Annals of Surgical Oncology. 2008;15:1600-1608.

    7. Cherr GS, Zimmerman PM, Wang J, Dosluoglu HH.  Depression, peripheral arterial disease, and screening cardiovascular events.  J Gen Intern Med.  2008;23:1544.

    8. Dosluoglu, HH.,  Wang, J., DeFranks-Anain, L., Rainstein, M., Nader, ND., A Simple Subclassification of ASA III Patients Undergoing Peripheral Revascularization Based on Functional Status, J Vasc Surg. 2008;47(4):766-773

    9. Cherr, GS., Zimmerman, PM., Wang, J., and Dosluoglu, HH., Association between depression and cardiovascular events after lower extremity revascularization in patients with peripheral arterial disease, Journal of General Internal Medicine. 2008;23(5):629-634

    10. Wang, J., Kulaylat, M., Rockette, H.,  Hassett, J., Rajput, A., Bullard Dunn, K.,  and Dayton, M. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer? Annals of Surgery, 2009; 249(4):559-563

    11. Meguerditchian, AN., Wang, J., Lema, B., Kraybill WG., Zeitouni, N., and Kane III, JM. Wide Excision or Mohs Micrographic Surgery for the Treatment of Primary Dermatofibrosarcoma Protuberans American Journal of Clinical Oncology, 2010 Jun;33(3):300-3

    12. Zhou, J.*, Yu, L.*, Gao, X.*, Hu, J.*, Wang, J., and Dai, Z. et al Plasma microRNA panel to diagnose Hepatitis B virus-related hepatocellular carcinoma, Journal of Clinical Oncology; 2011 Dec 20;29(36):4781-8,  *co-first authors.

    13. Wang, J., Dang, P., Raut, C.P., Pandalai, P.K., Maduekwe, U.N., Rattner D.W., Lauwers, D.Y., and Yoon, S.S. Comparison of a lymph node ratio based staging system to the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database, Annals of Surgery, 2012 Mar;255(3):478-85.

    14. Gu, FM, Gao, Q, Shi, GM, Zhang, X, Wang, J, Jiang, JH, Wang, XY, Shi, YH, Ding, ZB, Fan, J, and Zhou, J. Intratumoral IL-17+ Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma, Ann Surg Oncol, 2012 DOI 10.1245/s10434-012-2268-8

    15. Huang W, Hu J, Yang DW, Fan XT, Jin Y, Hou YY, Wang J, Yuan YF, Tan YS, Zhu XZ, , Bai CX, Wu Y, Zhu HG, Lu SH. Two MicroRNA Panels to Discriminate Three Subtypes of Lung Carcinoma in Bronchial Brushing Specimens. Am J Respir Crit Care Med. 2012 Oct 4. [Epub ahead of print]

    16. Carvajal-Carmona LG, Zauber AG, Jones AM, Howarth K, Wang J, Cheng T; APC Trial Collaborators; APPROVe Trial Collaborators; CORGI Study Collaborators; Colon Cancer Family Registry Collaborators; CGEMS Collaborators, Riddell R, Lanas A, Morton D, Bertagnolli MM, Tomlinson I. Much of the Population Genetic Risk of Colorectal Cancer Is Likely to Be Mediated Through Susceptibility to Adenomas. Gastroenterology. 2012 Sep 19. doi:pii: S0016-5085(12)01372-8. 10.1053/j.gastro.2012.09.016. [Epub ahead of print]

    17. Suntres, Z.E., Smith, M.G., Momen-Heravi, F., Hu, J., Zhang, X.,  Wu, Y., Zhu, H., Wang, J.,  Zhou, J. and Kuo W.P. Therapeutic uses of exosomes, Exosomes and Microvesicles, 2013, DOI: 10.5772/56522

    18. Wang, J., Carvajal-Carmona, L.G., Chu, JH., Zauber, A.G., et, al. Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genomewide Association Study, 2013, Clinical Cancer Research, 2013, Online first

    19. Hasson, R.M., Briggs,A., Carothers, A.M., Wang, J.,  Davids, J., Cho, N.L., and Bertagnolli, M.M., Estrogen Receptor  or  loss in the colon of Min/+ mice promotes crypt expansion and impairs TGF and HNF3signaling, 2013, Carcinogenesis. 2013 Oct 8, Online first

    20. Lee,YC, Yang, PJ, Zhong, Y, Clancy, T, Lin, M.T., and Wang, J. Lymph node ratio-based staging system outperforms the 7th AJCC system for gastric cancer: validation analysis with National Taiwan University Hospital cancer registry, 2013, Journal of Gastrointestinal Surgery (under review)

    21. Fairweather, M, Wang, J., Devlin, PM., et. al. Safety and Efficacy of Brachytherapy Delivered via Mesh Implantation for Deep Cavity Sarcomas, Annals of Surgery

    22. Zhang, Z., Wang, J., and Ji, D., et al Functional Genetic Approach Identifies MET, HER3, IGF-1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-positive Gastric Cancer, Cancer Research

    23. Wang, J., Sun, Y., and Bertagnolli, M., Comparison of gastric cancer survival between Caucasian and Asian patients treated in US: Results from Surveillance Epidemiology and End Results database, Journal of National Cancer Institute

    Jeffrey A. Cadeddu
    Title Professor of UT Southwestern Medical Center, Visiting Professor of SYSUCC (June 2014- June 2017)

    Jeffrey Cadeddu, M.D., is one of Texas’ leading urologists in the surgical treatment of prostate and kidney disorders. As Director of the UT Southwestern Clinical Center for Minimally Invasive Treatment of Urologic Cancer, he has performed more than 500 robotic/laparoscopic procedures on the prostate and introduced a number of firsts in the minimally invasive surgical treatment of kidney cancer and kidney disease.

    His training and extensive experience with kidney cancers in particular allow him to offer patients the full gamut of options in managing the disease without losing the kidney. Those options include ablation, an outpatient procedure in which the tumor is destroyed with a heated probe, rather than removed surgically. Dr. Cadeddu was the first in Texas to perform the procedure. He also has the most experience in North Texas with laparoscopic and robotic partial nephrectomy to remove kidney cancers.

    Along with an active clinical practice focused on minimally invasive procedures, Dr. Cadeddu maintains a robust research program aimed at developing new technologies and techniques that will make kidney surgery even less invasive while also maximizing kidney function better than what has traditionally been done.

    Dr. Cadeddu joined the faculty of UT Southwestern Medical Center, where he is a Professor of Urology and Radiology, in 1999 after receiving his initial medical training and completing residencies in urology and surgery at Johns Hopkins School of Medicine in Baltimore.

    As an expert in the treatment of kidney and prostate diseases, Dr. Cadeddu regularly lectures and educates other medical professionals on the latest developments in managing urologic conditions. In 2007, he received the Gold Cystoscope Award from the American Urological Association for his contributions to advances in kidney cancer treatment and the training of numerous academic urologists.

    Research Interest(s)

    Kidney Cancer, Laparoscopic Techniques, Prostate Cancer, Surgical Education


    1. Liu ZW, Olweny EO, Yin G, Faddegon S, Tan YK, Han WK, and Cadeddu JA. Prediction of perioperative outcomes following minimally invasive partial nephrectomy: role of the RENAL nephrometry score. World J Urol 31:1183, 2013.

    2. Seideman CA, Gahan J, Weaver M, Olweny EO, Richter M, Chan D, Cadeddu JA. Renal tumour nephrometry score does not correlate with the risk of radiofrequency ablation complications. BJU Int. 2013 Dec;112(8):1121-4.

    3. Bagrodia A, Harrow B, Liu ZW, Olweny EO, Faddegon S, Yin G, Tan YK, Han WK, Lotan Y, Margulis V, Cadeddu JA. Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. Urol Oncol. 2014 Jan;32(1):37.

    4. Antonelli JA, Bagrodia A, Odom C, Olweny EO, Faddegon S, Cadeddu JA. Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a 5-year, single-surgeon experience. Eur Urol. 2013 Sep;64(3):412-8.

    5. Olweny EO, Kapur P, Tan YK, Park SK, Adibi M, Cadeddu JA. Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology. 2013 Mar;81(3):679-84.

    6. Han WK, Tan YK, Olweny EO, Yin G, Liu ZW, Faddegon S, Scott DJ, Cadeddu JA. Comparison between magnetic anchoring and guidance system camera-assisted laparoendoscopic single-site surgery nephrectomy and conventional laparoendoscopic single-site surgery nephrectomy in a porcine model: focus on ergonomics and workload profiles.J Endourol. 2013 Apr;27(4):490-6.

    7. Yin G, Han WK, Faddegon S, Tan YK, Liu ZW, Olweny EO, Scott DJ, Cadeddu JA. Laparoendoscopic single site (LESS) in vivo suturing using a magnetic anchoring and guidance system (MAGS) camera in a porcine model: impact on ergonomics and workload. Urology. 2013 Jan;81(1):80-4.

    8. Liu ZW, Faddegon S, Olweny EO, Best SL, Jackson N, Raj GV, Zuzak KJ, Cadeddu JA. Renal oxygenation during partial nephrectomy: a comparison between artery-only occlusion versus artery and vein occlusion. J Endourol. 2013 Apr;27(4):470-4

    Jace S. Jones
    Title President of Cleveland Clinic, Visiting Professor of SYSUCC (June 2014 – June 2017)

    On December 1, 2014 Dr. Jones began his role as President of nine Cleveland Clinic Regional Hospitals and 18 Family Health Centers throughout Northeast Ohio. With recent mergers he now oversees 11 Hospitals and more than 20 Family Health Centers. He joined the Glickman Urological Kidney Institute in 2000, and became the Chairman of the Department of Regional Urology in 2007. Dr. Jones was Chief of Surgical Operations for the Regional Hospitals after serving in a similar role at Cleveland Clinic Fairview Hospital.

    Research Interest(s)

    Bladder cancer, elevated PSA, prostate cancer, nerve-sparing prostatectomy, vasectomy and sterilization


    1.Li YH, Elshafei A, Li J, Gong M, Susan L, Fareed K, Jones JS.Transrectal Saturation Technique May Improve Cancer Detection as an Initial Prostate Biopsy Strategy in Men with Prostate-specific Antigen <10 ng/ml. Eur Urol. 2014 Jun;65(6):1178-83.

    2.Li YH, Elshafei A, Li J, Hatem A, Zippe CD, Fareed K, Jones JS. Potential benefit of transrectal saturation prostate biopsy as an initial biopsy strategy: decreased likelihood of finding significant cancer on future biopsy.Urology. 2014 Apr;83(4):714-8.

    3.Grossgold E, Given R, Ruckle H, Jones JS.Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome? Urology. 2014 Feb;83(2):379-83.

    4. Elshafei A, Li YH, Hatem A, Moussa AS, Ethan V, Krishnan N, Li J, Jones JS.The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy. Prostate. 2013 Dec;73(16):1796-802.

    5. Ward JF, Diblasio CJ, Williams C, Given R, Jones JS. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. BJU Int. 2014 May;113(5):714-8. 6. Moussa AS, El-Shafei A, Diaz E, Gao T, Zaytoun OM, Fareed K, Ulchaker JC, Jones JS. Identification of the variables associated with pain during transrectal ultrasonography-guided prostate biopsy in the era of periprostatic nerve block: the role of transrectal probe configuration. BJU Int. 2013 Jun;111(8):1281-6.

    Chi-Fung Chan
    Title Since 2009, Prof. Chi-Fung Chan has been the Professor in the Queen Mary Hospital, the University of Hong Kong. His specialty is in Paediatric Haematology, Oncology, Haematopoietic and Stem Cell Transplantation.

    Since 2009, Prof. Chi-Fung Chan has been the Professor in the Queen Mary Hospital, the University of Hong Kong. His specialty is in Paediatric Haematology, Oncology, Haematopoietic and Stem Cell Transplantation.

    Children Cancer Foundation Scholarship (93-94)
    Management Society for Healthcare Professionals Scholarship (MSc. 96-99)
    Outstanding Staff & Team award, Queen Mary Hospital (1999, 2002 & 2003)
    Global Research Fellowship Award, Advanced in Neuroblastoma Research, Los Angeles, USA (2006)
    Endeavour Executive Award, Australian Government, Australia (2008)
    SIOP (International Society of Pediatric Oncology) Award, (2009)
    King’s (UK) / HKU Fellowship (2009-2010)
    ASPR (Asian Society of Pediatric Research) Best Research Award, Pediatric Academic Society (PAS) Annual Meeting, Denver, USA (2011)

    Research Interest(s)

    Prof. Chan has been studying the biology of human mesenchymal stem cells (MSCs), dendritic cells (DCs) and neuroblastoma cells (NB), in particularly how they interact with each other.


    218 published articles in Indexed Journals; 96 published abstracts; 9 book chapters; one book

    Selected Publications on Mesenchymal Stem Cells

    1.Fung MKL, Liang RHS, Chan GCF. Vincristine But Not Imatinib Could Suppress Mesenchymal Niche’s Support to Lymphoid Leukemic Cells. Leukemia Lymphoma 2010; 51(3):515-22.

    2.Tsao HW, Law HKW, Tu WW, Chan GCF, Lau YL. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cell 2010;28(5):939-54.

    3.Chan WK, Lau ASY, Li JCB, Law HKW, Lau YL, Chan GCF. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short term IFN-g challenge. Exp Hematol 2008 ;36(11):1545-55.

    4.Chan B, Leung MH, Yeung CW, Li J, Mo I, Chan GCF. Self-assembled collagen-human mesenchymal stem cell microspheres – Novel cell delivery devices for regenerative medicine and tissue engineering. Biomaterial 2007;28(31):4652-66.

    Selected Publications on Laboratory Studies for TCM

    1.Chan GCF, Cheung KW, Sze DMY. The Immunomodulatory and Anticancer Properties of Propolis. Clin Rev Allergy & Immuno 2012 Jun 17. [Epub ahead of print]

    2.Sze DMY, Chan GCF. Supplements for immune enhancement in hematologic malignancies. Hemtaology (Am Soc Hematol Educ Program) 2009; 313-9.

    3.Yang M, Chan GCF, Deng RX, Liu C. An herbal decoction of Radix Astragali and Radix Angelicae promotes haematopoiesis and thrombopoiesis. J Ethnopharma 2009;124(1):87-97.

    4.Chan GCF, Chan WK, Sze DMY. The effects of b-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2(1):25.

    5.Chan WK, Cheung C, Law H, Lau YL, Chan GCF. Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. J Hematol Oncol 2008; 21;1(1):9,1-12.

    Selected Clinical Papers on Pediatric Neurogenic Tumors

    1.Liu APY, Shing MMK, Yuen HL, Li RCH, Ling SC, Luk CW, Ha SY, Li CK, Chan GCF. Timing of adjuvant radiotherapy and treatment outcome in childhood ependymoma.  Pediatr Blood Cancer (in press)

    2.Ma M, Ye JY, Deng RX, Dee CM, Chan GCF. Mesenchymal Stromal Cells May Enhance Metastasis of Neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 Signaling. Cancer Letter 2011 Jul 7.

    3.Chan GCF, Shing MMK, Yuen HL, Li RCH, Li CK, Luk CW, Ha SY, Li CK. The management and outcome of childhood brain tumors: the Hong Kong experience. J Jap Soc Clin Oncol. 2011;46(3): 1447-1450.

    4.Cheuk DK, Lee TL, Chiang AK, Ha SY, Chan GCF. Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children. J Neurooncol. 2008;86(3):337-47.

    5.Khong PL, Kwong DLW, Fong D, Fung A, Chan GCF. White matter anisotropy in the assessment of treatment-induced neurotoxicity in childhood cancer survivors: association with neurocognitive function. J Clin Oncol 2006;24(6):884-90.

    Selected Clinical Papers on Pediatric Haematology

    1.Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GCF, Novitzky N, Wong RS, Krassova S, Allen G, Jiang HY, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Gloria Vigliani, Brennan A, Luk A, Pierce GF. Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B.N Engl J Med. 2013;369(24):2313-23.

    Franco Cavalli
    Title Director of the Oncology Institute of Southern Switzerland, Visiting Professor of SYSUCC (July 2013 – June 2014)

    Currently he is the Director of the Oncology Institute of Southern Switzerland at Ospedale San Giovanni, in Bellinzona. At the beginning of his carrier his main interest was leukemia, at that time he represented Switzerland in the CALGB. Later on his research was concentrated on breast cancer, while for the last ten years malignant lymphoma has become his major interest. Since 1981 he organizes every third year the International Conference on Malignant Lymphoma in Lugano, Switzerland, which has become the main gathering point worldwide both for clinical as well as for basic research in lymphomas. He was the editor-in chief of Annals of Oncology and was a founder of the IELSG. Author or co-author of more than 400 scientific papers and of four books, among them together with S. Kaye and H. Hansen, the Text Book of Medical Oncology. He has received 12 International Awards, among them the Pezcoller Award, the NDDO Honorary Award, the Greidinger Award in Haifa (Israel) and the Waldman Award in Omaha, Nebraska.

    Research Interest(s)

    His research priorities are new drugs and new treatment modalities, haematological malignancies, including lymphomas, and breast cancer.


    1.  Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial.Blood. 2002 Apr 1;99(7):2541-4.

    2.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.Blood. 2003 Apr 1;101(7):2489-95. Epub 2002 Nov 27.

    3.  Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.Blood. 2003 Oct 15;102(8):2741-5. Epub 2003 Jul 3.

    4.  Cancer in the developing world: can we avoid the disaster?Nat Clin Pract Oncol. 2006 Nov;3(11):582-3.

    5.  Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study.Lancet Oncol. 2008 Aug;9(8):721-9. doi: 10.1016/S1470-2045(08)70194-3.

    6.  The World Cancer Declaration: a roadmap for change.Lancet Oncol. 2008 Sep;9(9):810-1. doi: 10.1016/S1470-2045(08)70213-4.

    7.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18.

    8.  Patterns of survival of follicular lymphomas at a single institution through three decades.Leuk Lymphoma. 2010 Jun;51(6):1028-34. doi: 10.3109/10428191003743460.

    9.  Targeted therapy in lymphoma.J Hematol Oncol. 2010 Nov 23;3:45. doi: 10.1186/1756-8722-3-45.

    10. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.Blood. 2011 Feb 3;117(5):1595-604. doi: 10.1182/blood-2010-01-264275. Epub 2010 Nov 29.

    11. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.J C O . 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187.

    12. Incidence, risk factors and outcome of histological transformation in follicular lymphoma.Br J Haematol. 2012 Apr;157(2):188-96. doi: 10.1111/j.1365-2141.2012.09054.x. Epub 2012 Feb 20.

    13. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study.J C O. 2013 Feb 10;31(5):565-72. doi: 10.1200/JCO.2011.40.6272.

    14. An appeal to world leaders: stop cancer now.Lancet. 2013 Feb 9;381(9865):425-6. doi: 10.1016/S0140-6736(13)60059-8. Epub 2013 Feb 4. 

    Dongfeng Tan
    Title Professor of Pathology in MD Anderson Cancer Center, Visiting Professor of SYSUCC (March 2014 – March 2017)

    Board Certifications
    Diplomat of American Board of Pathology, combined Anatomic & Clinical Pathology
    Diplomat, U.S. National Board of Medical Examiners
    Texas State Board of Medical Examiners
    U.S. Federal Medical Board Exam Certification

    Research Interest(s)
    Education Medical School: Tongji Medical University
    Clinical Residency: Yale University Medical Center
    Clinical Fellowship: Memorial Sloan-Kettering Cancer Center

    1. Wiseman SM, Rigual NR, Hicks WL, Popat SR, Lore JM, Douglas WG, Jacobson MJ, Tan D, Loree TR. Parathyroid carcinoma: a multicenter review of clinicopathologic features and treatment outcomes., Ear Nose Throat J, 83:2004

    2. Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer., J Clin Oncol, 22:2004

    3. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma., Hepatogastroenterology, 51:2004

    4. Hawthorn L, Stein L, Varma R, Wiseman S, Loree T, Tan D. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma., Head Neck, 26:2004

    5. Said M, Wiseman S, Yang J, Alrawi S, Douglas W, Cheney R, Hicks W, Rigual N, Loree T, Spiegel G, Tan D. Tissue eosinophilia: a morphologic marker for assessing stromal invasion in laryngeal squamous neoplasms., BMC Clin Pathol, 5:2005

    6. Okada H, Kimura MT, Tan D, Fujiwara K, Igarashi J, Makuuchi M, Hui AM, Tsurumaru M, Nagase H. Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas., Int J Oncol, 26:2005

    7. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?, Int J Cancer, 114:2005

    8. Alrawi SJ, Tan D, Stoler DL, Dayton M, Anderson GR, Mojica P, Douglas W, Hicks W, Rigual N, Loree T. Tissue eosinophilic infiltration: a useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia., Cancer J, 11:2005

    9. Khoury T, Hurd T, Tan D. Phyllodes tumor with pseudoangiomatous stroma hyperplasia., Breast J, 11:2005

    10. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)., Lung Cancer, 49:2005

    CJ Tseng
    Title Vice President of Chung Shan Medical University Hospital, Visiting Professor of SYSUCC (January 2014 – December 2016)

    Dr. CJ Tseng is the vice president and professor of gynecological cancer in Chung Shan Medical University Hospital in Taiwan. In 1992 he has been trained in Gynecological Cancer Center of Stanford University Hospital. After he came back to Taiwan, he had worked as the chief physician of gynecological cancer in Chang Gung Memorial Hospital for 20 years.

    Research Interest(s)
    Chun Liang
    Title Associate Professor in the Hong Kong University of Science and Technology, Visiting Professor of SYSUCC (April 2013 – March 2016)

    In 1993 Prof. Chun Liang received his Doctoral Degree in Biology in Brown University in the United States. Since 1998 he has been working in the Hong Kong University of Science and Technology and now he is the Associate Professor and Associate Director of the Center for Cancer Research.

    Research Interest(s)

    Mechanism and cell cycle control of DNA replication in the budding yeast Saccharomyces cerevisiae; regulation of DNA replication in normal and cancer cells; molecular cancer detection and anticancer drugs.


    1. Huo L., R. Wu, Z. Yu, Y. Zhai, X. Yang, T. Chan, J. Yeung, J. Kan, and *Liang C. (2012) The Rix1 (Ipi1p-2p-3p) Complex Is a  Critical Determinant of DNA Replication Licensing Independent of  Their Roles in Ribosome Biogenesis. Cell Cycle 11, 1325-1339.

    2. Liu, C., Wu, R., Wei, Z., Wang, J., Tye, B., *Liang, C., and *Zhu G. (2012) Structural Insights into the Cdt1-Mediated Mcm2-7 Chromatin Loading. Nucleic Acids Res. 40, 3208-3217  (*co-corresponding authors).

    3. Wu, R., Wang, J., and Liang, C. (2012) Cdt1p,  through its interaction with Mcm6p, is required for the formation, nuclear accumulation and chromatin loading of the MCM complex.J. Cell Sci.125, 209-219.

    4. Geng, H., Law, P., Ng, M., Li, T., Liang, L., Ge, T., Wong, K.,Liang, C.,Ma, R., So, W., Chan, J., Ho, Y. (2011) APOE Genotype-Function  Relationship: Evidence of 2491 A/T Promoter Polymorphism Modifying Transcription Control but Not Type 2 Diabetes Risk. PLoS ONE 6, e24669-e24669

    5. Zhai, Y., Yung, P., and Liang. C. (2011) Cell cycle control of DNA replication by phosphorylation and dephosphorylation of  replication-initiation proteins in budding yeast. Chapter 6 in “Fundamental Aspects of DNA Replication”. InTech Publisher; Ed. J.  Kušić-Tišma; pp87-106.

    6. Lai, F.Q., Wu, R.T. Wang, J.F., Li, C.M., Zou, L., Lu Y.J., and Liang, C. (2011)   Far3p domains involved in the interactions of Far proteins and pheromone-induced cell cycle arrest in budding yeast. FEMS Yeast Res. 11, 72-79.

    7. Zhang J., Yu, L., Wu., X., Zou., L. Sou, K.K.L, Wei, Z., Cheng X., Zhu, G.*. and Liang C.* (2010) The Interacting Domains of hCdt1 and hMcm6 Involved in the Chromatin Loading of the MCM Complex in Human Cells. CellCycle 9, 4848-4857 (*co-corresponding authors)

    8. Ma,  L.J., Zhai, Y.L., Feng, D.R., Chan, T.C., Lu, J.L., Fu, X.R., Wang, J.F., Chen, Y.H., Li, J.N., Xu, K. and Liang, C. (2010) Identification of Novel Factors Involved in or Regulating Initiation of DNA Replication by a Phenotypic Screen in Saccharomyces cerevisiae. Cell Cycle 9, 4399-4410.

    9. Zhai, Y.L. Yung, P., Huo L. and Liang C. (2010) Cdc14p resets the competency of replication licensing by dephosphorylating multiple initiation proteins.  J. Cell Sci. 123, 3933-3943.

    10. Cheng, X., Xu, Z., Wang, J.F., Zhai, Y.L, Lu, Y.J, and Liang, C. (2010) ATP-dependent Pre-replicative Complex Assembly Is Facilitated by Adk1p in Budding Yeast.. J. Biol. Chem. 285, 29974-29980.

    11. Wei, Z., Liu, C.D., Xu, N.N., Wu, X. Zhou, B., Liang, C.*, and Zhu, G.*(2010)Characterization and structure determination of the Cdt1 binding domain of human minichromosome maintenance (Mcm) 6. J. Boil. Chem. 285, 12469-12473 (accelerated publication)(*co-corresponding authors).

    12. Wang, J.F., Wu, R.T., Lu, Y.J. and Liang, C. (2010) Ctf4p facilitates Mcm10p to promote DNA replication in budding yeast. Biochem. Biophys. Res. Commun. 395, 336-341.


    Sharlene Gill
    Title Associate Professor of Medicine in the University of British Columbia, Visiting Professor of SYSUCC (October 2012 – September 2015)

    Prof. Sharlene Gill is the Associate Professor of Medicine in the University of British Columbia.

    Research Interest(s) Colorectal Cancer
    Hepatobiliary Malignancies
    Pancreatic Cancer
    Phase II/III Clinical Trials
    Health Outcomes Research


    University of British Columbia, 1992, BSc (Pharm)
    University of British Columbia, 1996, MD
    Harvard School of Public Health, 2003, MPH
    UBC Internal Medicine, 1999
    UBC Medical Oncology, 2001
    Mayo School of Medicine, GI Oncology, 2003


Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.